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I Introduction
I.1 Endotoxin and inflammation
Inflammation is a defense reaction of the body to injury or invasion by
disease-producing organisms called pathogens. It is normally a beneficial, and
complex physiological process which ensures that the tissues are protected against
pathogens, and other damaging factors. Each component of the acute
inflammatory reaction (e.g. vasodilatation of the blood vessels, heat, pain) is
brought about by the regulated synthesis and release of numerous mediators
(biogenic amines, endogenous peptides, lipids and proteins). In some cases,
however, the inflammatory response is excessive and gets out off the control
exerted by natural inhibitors, which inevitably leads to complications such as
organ dysfunction and shock.
Bacterial wall components are the main activator of the host response to
pathogenic insults. When administered in animal models, these wall components,
especially the endotoxins, are capable of eliciting many of the manifestations of
sepsis. They serve as trigger for the host response and for the development of the
inflammatory cascade. In humans, endotoxins are responsible for the most severe
septic shocks refractory to therapy and are accompanied by a high mortality rate
(up to 90% of patients) [93].
Endotoxins are amphiphilic lipopolysaccharides, which form, along with
phospholipids and proteins, the outer membrane of Gram negative bacteria (see
Figure 1). The endotoxin is composed of a polysaccharide chain covalently bound
to a lipidic component, the so-called lipid A [125]. The outer and inner core of the
oligosaccharide is located closed to the cell membrane (see Figure 1), in contrast
to the variable sugar chain (each endotoxin possesses its own O-specific chain
characterised by its length and chemical composition), which stands out like a hair
from the surface of the bacteria. Lipid A and the core regions are conserved within
different bacterium serotypes. The toxic and immune stimulating effect of the
endotoxin is linked to the lipid A. The outer core is used as receptor for phages
whereas the inner core plays a role in the activation of complement system and is
able to modulate the biological activity of lipid A (see Figure 1). 
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Figure 1: General structure of LPS (Salmonella) after Formsgard A. (1990)
       : D-glucose;         : 2-keto-3-deoxy-mano-octanoate;          : N-acetyl-D-glucosamine;
       :heptose;          : D-galactose;           : D-glucosamine;  P: phosphate;
               : fatty acid
n: ranging from zero to as many as 40
I.2 Cytokines and cardiac contractile function
Systemic (as well as intracardial) inflammation, as it occurs through viral
infection, sepsis, or coronary ischemia is able to induce considerable short- or
long-term impairment of the myocardial function [20, 76, 94]. Endogenous release
of proinflammatory (or stress-activated) cytokines in response to bacterial
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lipopolysaccharides promotes the initial phase of the immune response and is
responsible for the time-dependent depression of cardiac contractile function.
Proinflammatory cytokines, such as TNFα and IL-1β [20, 76, 95, 97] are
secretory polypeptides synthesised by macrophages, leukocytes, monocytes [19],
endothelial cells, and even heart muscle cells [70, 71]. Clinical investigations
showed that high level of cytokines (as TNFα) are present in serum of septic
patients, and overexpressed in patients with advanced heart failure [69]. In vitro,
these cytokines produce direct reversible negative inotropic effects on the
mammalian heart (i.e. a diminution of contraction amplitude or force), for
example in the isolated papillary muscle of hamster [43]. 
During the last 10 years experimental work with isolated hearts and
cardiomyocytes considerably contributed to the development of a rich data base
relative to the contractile dysfunction in septic hearts and its underlying cellular
mechanisms. Toxins and inflammatory mediators have been demonstrated to
interfere with several inotropic pathways. Among these inotropic axes which have
been found to be impaired in the inflammation state are: the α1-adrenoreceptor
phosphoinositide pathway [124], the β-adrenoreceptor/adenyl cyclase pathway
[15, 57], the NO-cGMP pathway [6, 101], the sphingomyelin pathway [115], and
as the common final target for the contractile depression, the calcium homeostasis
[59, 80].
However, despite the growing evidence that proinflammatory cytokines contribute
to the contractile dysfunction occurring in many cardiac pathologies, the precise
underlying mechanisms, and their relative importance remain to be established.  
I.3 Cytokines and the metabolism of glucose
An additional aspect that has received little attention so far, is that
inflammatory reactions may also disturb the energy metabolism of the heart, and
that this may contribute to the mechanical dysfunction observed under such
conditions. 
Although the heart utilises a variety of energy substrates (see Figure 2),
glucose plays a particular role in the maintenance of the mechanical function. This
is especially manifest in pathophysiological situations. Animal studies showed
that glucose (or a pharmacological stimulation of glucose metabolism) – in
contrast to fatty acids and other substrates – exerts a positive effect on the
functional recovery after ischemia and reperfusion [96, 114]. In the same way, the
impaired contractile function of hearts isolated from diabetic animals can be
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restored through a selective stimulation of glucose metabolism. Clinical studies
showed that even in humans, a reinforcement of myocardial glucose utilisation, or
a diminution of fat utilisation, ameliorates heart function.
Figure 2: Energetic metabolism in the myocardium
Interestingly, a number of investigations have provided evidence that
inflammation-induced signals – cytokines, nitric oxide (NO), sphingomyelin
derivatives – can per se strongly influence the metabolism of glucose  in insulin
sensitive tissues, especially skeletal muscle [13, 14] and fat tissue [51, 86, 91,
121]. Recent studies indicate that this may also apply to the heart. Thus, in
isolated rat hearts, it was shown that NO and its second messenger cyclic
guanosine monophosphate (cGMP) inhibit cardiac glycolysis [37]. In addition,
preliminary work performed in our laboratory indicates that inflammatory
cytokines, as well as sphingomyelin derivatives inhibit the insulin-stimulated
glucose transport of isolated cardiomyocytes (Thurner et al., manuscript in
preparation).
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In view of the potential influence of inflammatory signals on cardiac glucose
utilisation, and of the importance of glucose as an energy substrate under certain
conditions, it is conceivable that a generalised or local, i.e. myocardial,
inflammatory reaction also influences heart function via effects on the metabolism
of the sugar. However, to my knowledge, this possibility has not yet been
investigated.
I.4 Aims and organisation of the thesis
Considering the present state of knowledge in the field of cardiac
inflammation (see above), it is reasonable to hypothesise that proinflammatory
cytokines could affect the glucose metabolism of the heart and thereby reduce its
contractile capacity.
The specific aims of the present studies were therefore:
- to develop a reliable model of an acute heart inflammation in vivo using a
bacterial lipopolysaccharide injection in rats.
- to investigate the effects of an acute inflammation on the metabolism of the
glucose in hearts isolated from these animals, and the role of possible
metabolic changes in the cardiac depression;
- to evaluate the influence of LPS-treatment on glucose uptake, and
glycolysis at two different experimental levels: isolated hearts and single
cardiomyocytes;
- to determine the signalling pathways involved, especially the role played
by nitric oxide, and sphingomyelin derivatives in these processes (see
Figure 3).
The present work was part of the concerted research project SFB 542
“Molecular mechanisms of inflammation: Cytokines, signal transduction and
pathophysiologic consequences“ which is financed by the Deutsche
Forschungsgemeinschaft (German Society for Scientific Research), and chaired
by Prof. P.C. Heinrich (Institute of Biochemistry, Aachen). The general aim of all
the participating projects is to determine the molecular mechanisms underlying
changes induced in organs and tissues in the course of acute and chronic
inflammation, in order to create a basis for the development of new therapeutic
strategies. 
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Figure 3: Experimental concept
Rats treated with Lipopolysaccharide from Salmonella typhimurium (intravenous injection)
were used as a model of an acute inflammation. The aim of our study was to investigate the
effects of the endotoxin on the metabolism of the glucose in hearts isolated from the
experimental animals 6 hours after the LPS injection, and the role of possible metabolic
changes in the cardiac hypocontractility. In addition it was planned to determine the signalling
pathways involved in these pathological processes by using specific inhibitors, such as the
nitric oxide synthase (NOS)-inhibitor Nitro-L-arginine methylester (L-NAME), and the
ceramidase inhibitor N-oleyl-ethanolamine (NOE).
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II Materials and methods
II.1 Materials
II.1.1 Chemicals and consumables
• Salts:
Bis-acrylamide; (NH4)2S2O7: from Bio-Rad (Munich, Germany). AgNO3; CaCl2; H3BO3;
KCl; KHCO3; K2CO3; KH2PO4; K2HPO4; KOH; MgSO4; Na2B4O7; NaCl; Na2CO3; Na-
HEPES; NaH2PO4, Na2HPO4; NaN3; NaOH; Na2S2O3; Na2SO4; Titriplex III (EDTA): from
Merck (Darmstadt, Germany) HEPES; Sodium dodecyl sulfate (SDS); Tris-Base; Tris-
HCl: from Sigma (Munich, Germany).
• Enzymes:
    All enzymes were from Boehringer (Mannheim, Germany).
• Antibodies:
Primary antibody: Polyclonal mouse anti-rat-iNOS: from Sigma (Munich, Germany).
Secondary antibody: Goat anti-rat-IgG, peroxidase conjugate: from Sigma (Munich,
Germany).
• Radiochemicals:
    2- [3H]-D-Glucose and 3- [3H]-D-Glucose from Amersham (Braunschweig, Germany).
• Biochemicals:
 NADH, and kaolin-activated reagent (activator: cephalin) from Boehringer (Mannheim,
Germany). Isoproterenol; ß-hydroxybutyric acid; dichloroacetate; SNAP from Sigma
(Munich, Germany). ECL-Western Blotting reagents from Amersham (Braunschweig,
Germany). Pyruvic acid sodium salt from Merck (Darmstadt, Germany). Low-fat milk
powder from Nestlé (Frankfurt on the Main, Germany). Molecular weight marker mix;
prestained Coomassie-Brillant Blue; TEMED; dye reagent from BioRad (Munich,
Germany). Calf insulin (generous gift from Prof. A. Wollmer, Institute of Biochemistry,
RWTH Aachen, Germany).
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• Solvents and other liquids:
 Triton X-100; Tween 20 from Sigma (Munich, Germany). HCl (concentrated); zink
chloride; perchloric acid from Merck (Darmstadt, Germany). Quickzint 212 (emulsifying
gel scintillator)  from Zinsser Analytik (Frankfurt on the Main, Germany).
• Chromatography gel:
 Dowex AG1-X8 (200-400 mesh) from BioRad (Munich, Germany).
II.1.2 Experimental animals
Male Sprague-Dawley rats (300 to 400g, Charles River) were acclimated to
our animal facilities for 7 days at constant temperature (20 ± 2 °C), exposed to a
12h-light/12h-dark cycle (light from 07h00) and fed ad libitum on a chow diet
comprising approximately 4.9 % carbohydrate, 19 % protein and 3.3 % fat.
Animals had free access to drinking water. Only healthy animals free from
obvious disease were included in the studies. The animals were acquired and used
in compliance with § 6 of the German Animal Protection Law, and the study was
reviewed and approved by the appropriate authority (Bezirksregierung Cologne;
project #: 23.203.2-AC 8).
II.1.3 Equipment
●   Scale: RC 250 S, Sartorius
●   Bath thermostat: U3, Julabo
●   Centrifuges: 101 M and 2 MK Sigma; Z 200, Hermle;
L7, Beckmann (Rotors Ti60 and Ti70)
●   Micropipette puller: Model p-97, Sutter Instrument
●   Osmometer: Osmomat 030, Gonotec
●   Patch-clamp amplifier: EPC9, Heka
 ●   pH meter: 744, Metronohm
●   Scintillation counter: 1409, Wallac
●   Sonifier: B-12 Branson Sonic Power
●   Spectral photometers: Lambda 5, Perkin-Elmer 
Spectra shell, SLT Labinstuments
●   Western Blot-Chamber: LKB Brommer
 ●   Chart recorder: Mark VII, Watanabe
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II.2 Methods
II.2.1 Experiments with isolated hearts
II.2.1.1 Experimental model
As model for an acute inflammation reaction the rats were treated with
bacterial lipopolysaccharide (LPS) from Salmonella typhimurium. In a first series
of experiments, a previously described protocol of endotoxin was used
(intraperitoneal administration to conscious rats of 0.5 mg LPS dissolved in 1ml
saline per kg body weight [99]). However, in our hands, the occurrence and
degree of contractile depression observed ex vivo (i. e. in perfused hearts isolated
6 hours after the LPS injection) turned out to be highly variable. We therefore
tried out several modifications to this protocol and found that intravenous
application of LPS (1mg/kg body weight into the caudal vein, applied in 1ml
sterile saline) to rats previously anaesthetised in ether atmosphere (2% vol/vol, i.e.
2ml ether in a 2l box) (Figure 4) caused a very reproducible reduction in left
ventricular developed pressure (LVDP), as measured in perfused hearts isolated 6
hours after the endotoxin injection, without provoking any mortality. At the end of
this period, hearts were isolated and perfused, as detailed below. For a more
detailed validation of this inflammation model: see Results, section III.1.
Figure 4: Intravenous injection in the rat tail
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II.2.1.2 Rat blood analyses
All blood samples were taken from the abdominal space (using a millilitre
syringe) in the course of the heart preparations, right after cutting the vena cava
inferior. The concentration of glucose, lactate, cortisol and fatty acids (sections
II.2.1.2.1 to II.2.1.2.5 ) were kindly performed by the team of Prof. A.M. Gressner
(Dept. of Clinical chemistry, RWTH Aachen).
II.2.1.2.1 Plasma insulin measurements
Blood samples were collected in EDTA test tubes (Sarstedt, ref. 05.1073) and
plasma was obtained by centrifugation (2000 g for 10 min) and stored at -80°C for
later analyses. Plasma-immunoreactive insulin was measured in duplicate using an
ELISA kit for insulin (Mercodia, Uppsala, kit n° 10-1137-01). The procedure was
as follows: the ELISA test was performed with insulin standards (0.15- 5.5µg/l)
and rat plasma samples. 30 µl of sample or standard and 50 µl anti-insulin
antibody conjugate (peroxidase-conjugated mouse monoclonal anti-insulin) were
pipetted into each well of the ELISA plate and incubated on a shaker for 2 h at
room temperature. After a washing step (with wash medium provided with the kit)
to remove unbound enzyme labelled antibody the bound conjugate was detected
by reaction with 3, 3´, 5, 5´-tetramethylbenzidine (TMB). The reaction was
stopped after 30 min by adding acid (H2SO4 , 1M) to give a colorimetric endpoint
that was read spectrophotometrically at 450 nm (Spectra shell).
II.2.1.2.2 Cortisol measurements
Blood samples were collected in standard S-Monovette (Sarstedt, Germany,
Ref. 04.1935) and centrifuged at 2000 g for 10 min to obtain serum. The cortisol
concentration in rat serum (300 µl) was determined with the ADVIA Centaur
system (diagnostic kit ref. 110776 and automate Centaur) from Bayer Diagnostics
(Leverkusen, Germany). This is a competitive immunoassay. The cortisol in
sample compete with the cortisol marked with acridinium contained in the Lite
reagent (provided with the kit) for binding to the rabbit polyclonal anti-cortisol
antibody in the solid phase.
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II.2.1.2.3 Lactate
Blood samples were collected in standard S-Monovette (Sarstedt, ref.
05.1073) containing sodium fluoride (1mg/ml blood) and EDTA (1.2 mg/ml
blood) and centrifuged at 2000 g for 10 min. The method used for lactate content
determination consisted of an enzymatic reaction to convert lactate to pyruvate.
The hydrogen peroxide produced by this reaction was then used in an enzymatic
reaction to generate a colored dye [9]. 
Test principle: 
                            LOD
L-Lactate  +  O2             Pyruvate  +  H2O2
                                                                                                          POD
H2O2  +  H donor  +  4-aminoantipyridine+                 chromogen+  +  2H2O
LOD:Lactatoxidase, POD:Peroxidase. 
The intensity of the color formed is proportional to the L-lactate concentration
and was automatically measured (Analyser Hitachi 917).
II.2.1.2.4 Glucose
Glucose im rat serum and perfusion medium was analysed with the
commercial kit Gluco-quant (ref. 1876899) provided by Roche (Mannheim,
Germany) associated with the analyser Hitachi 917.
Test principle [17]: 
Glucose is phophorylated by the hexokinase to Glucose-6-phosphate, which is
oxidised into gluconate-6-phosphate. The speed of NADPH production is
proportional to the glucose concentration.
                            HK
Glucose  +  ATP             Glucose-6P  +  ADP
                                                               G-6P.DH
 Glucose-6P    +  NADP+               Gluconate-6P  +  NADPH     +  H+ 
HK:Hexokinase, G-6P.DH: Glucose-6-phosphate dehydrogenase. 
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II.2.1.2.5 Non esterified fatty acids
Quantification of Non-Esterified Fatty Acids (NEFA) in rat serum (300 µl)
was performed with the commercial kit (ref. 1383175) of Roche (Mannheim,
Germany).
Test principle:
                                              AcylCS
NEFA  +  ATP  + CoA             AcylCoA  +  AMP  +  PPi
                                               ACOD
AcylCoA   +  O2                  AcylCoA   +  H2O2
                                                                             POD
H2O2  +  4-Aminoantipyridin  +  TBHB              red color  +  HBr +  2H2O
The intensity of the red coloration measured photometrically at 546nm is
proportional to the concentration of NEFA.
Acyl CS: Acyl-CoA-synthetase; ACOD: Acyl-CoA-oxidase; POD:
peroxidase; TBHB: 2,4,6-Tribrom-3-hydroxybenzoacid.
II.2.1.2.6 Partial thromboplastin (PTT) time
Blood was first collected in disposable syringes containing 0.11 M sodium
citrate. Immediately after the blood sample was obtained and well mixed, it was
centrifuged for 10 min at 2000 g and the supernatant was collected. 0.1 ml citrated
plasma and 1.0 ml PTT reagent (Boehringer Mannheim, ref 126551) were mixed
in prewarmed test tubes (37 °C). After 3 min incubation at 37 °C CaCl2 (0.1 ml,
0.025M) was added to determine the time (in seconds) that elapses from the
addition of calcium to the onset of clotting (see Figure 5).
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Figure 5: PTT time measurement
   Determination of the PTT-time was conducted in three steps:
⇒ step n°1: starting of the chronometer after mixing citrate plasma to the PTT reagent in
prewarmed test tubes by the rolling of a steel ball
⇒ step n°2: addition of calcium chloride, after 3 min incubation at 37 °C
⇒ step n°3: determination of the coagulation time by stopping the chronometer when the
movement of the steel ball was inhibited by the clotting
II.2.1.2.7 Blood picture
Determination of blood cells numbers was made with an electronic counter
(type Celltek m, Bayer Diagnostics, Leverkusen-Germany). 
II.2.1.3 Isolated heart procedure
The principle of this technique developed at the end of the 19th century [84]
consists in opening the chest of an anaesthetised animal, to quickly take the
beating heart out of the body and to cannulate it via the aorta to perfuse it in a
retrograde fashion. The saline buffer used for this perfusion is saturated with
95% O2~5% CO2, and set at a hydrostatic pressure corresponding to 85 cm water
column to provide a high flow, and assure a sufficient oxygen supply.
0.1 ml citrate plasma 
+ 0.1 ml PTT reagent
CHRONOMETER
         
         
0.1 ml CaCl2 
0 : 00 : 00
CHRONOMETER
CHRONOMETER
        
        
coagulation time: 27 sec
Step n°1                                        Step n°2                                               Step n°3
0 : 03 : 00 0 : 03 : 27
WARMING PLATE
PLASTIC 
TUBE
STEEL 
BALL
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This technique allows to observe the effects of any controlled parameter on
the cardiac physiology (changes of temperature or ion concentration) or to record
the influence of chemicals on the myocardial contractility without any
interferences of the in vivo neuro-hormonal regulation. 
II.2.1.4 Experimental setup and heart perfusion
6 hours after the LPS injection the rats were anaesthetised during 5 minutes in
an ether atmosphere (2% vol/vol, i.e. 2ml ether in a 2l box). After thoracotomy,
the vena cava inferior was severed and the diaphragm opened. The thymus was
removed, the aorta ascendens, the pulmonary arteries and venae were cut. Hearts
were rapidly excised and arrested in ice-cold (4 °C) Krebs-Henselheit bicarbonate
buffered solution (pH 7.4) with the following composition (mM): NaCl 128.5;
NaHCO3 25; D-glucose 5.6; KCl 4.7; KH2PO4 1.2; MgSO4 1.2; EDTA 0.5; CaCl2
2.5.
The total non perfused preparation time was kept under a maximum of 2 to
3 minutes in order to avoid a severe (i.e. prolonged) ischemia. Non-cardiac (e.g.
connective) tissue was removed, and the hearts were cannulated via the ascending
aorta for retrograde perfusion by the Langendorff method [84] using the same
buffer as above, kept at 37 ± 0.5 °C and continuously gassed with 95% O2 and 5%
CO2. Hearts were suspended in a temperature-controlled chamber maintained at
37 °C ± 0.5 °C (Figures 6 and 7). All the experiments were carried out with a
constant perfusion pressure of 62 mm Hg (84 cm H2O), which permits to keep the
aortic valve closed and to supply the coronary arteries with the oxygenated
medium. A 3-way valve fixed onto the cannula allowed a switch between different
perfusion media, or perfusion modes (non-recirculating vs. recirculating).
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Figure 6: Experimental setup for perfusion experiments with isolated rat hearts
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II.2.1.5 Assessment of cardiac function
The left atria were carefully removed and a latex balloon filled with water
(~ 0.15 ml) was inserted into the left ventricle through the mitral valve. The balloon
was connected to a disposable pressure transducer (Model I-93-II-096, PVB
Medizintechnik, Germany) and a Watanabe chart recorder. Heart rate, LVDP,
+dP/dt and -dP/dt could be simultaneously recorded (Figure 7). Coronary flow was
measured by timed collection of the coronary effluent at regular intervals. All these
parameters of heart function were recorded throughout the perfusion period.
Figure 7: Schematic representation of setup used for functional and metabolic measurements
in isolated hearts
The perfusion pressure was achieved using a water column (W) to maintain a constant
perfusion pressure of 62 mm Hg. The perfusion reservoirs containing non-radioactive Krebs
buffer (1000 ml, for the non-recirculating perfusion mode) and radioactive Krebs buffer
(100 ml, for metabolic measurements in recirculating mode) were placed in a thermostatic
water bath (WB). The temperature in the perfusion chamber was kept at 38 °C. Both perfusion
reservoirs were continuously bubbled with a gas mixture (Carbogen, i.e. 95% O2 + 5% CO2 ).
The three-way valve fixed onto the aortic cannula was used to switch between the two circuits.
The radioactive buffer was locked in the closed system and recirculated via a peristaltic pump.
For further details: see text.
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II.2.1.6 Experimental design of experiments with isolated hearts 
In the course of this work, three different perfusion protocols were used in
accordance with their respective aim. 
The first experimental design was used to investigate the effects of the in vivo
LPS treatment on cardiac glucose metabolism . After an equilibration period of
retrograde perfusion (10 min, ‘Preperfusion’ in Figure 8, panel A) to wash out any
blood and reach a functional steady state, the hearts were perfused with a
recirculating Krebs-Henselheit bicarbonate buffer (100 ml) containing glucose
(5.6 mM) as the sole energy substrate (for a total of 50 min; Figure 8). Ten min
after the beginning of this recirculating perfusion, radioactive glucose tracer (2-
[3H]-D-glucose or 3-[3H]-D-glucose – see below – 2 µCi in a volume of 500 µl)
was injected into the medium; after another 26 min insulin (17 nM) was added.
The second protocol was applied to identify modifications in the substrate
competition following the endotoxin treatment of the rats. For this purpose, we
used the same perfusion timing as above, but added a second substrate (β-
hydroxybutyrate, used as so-called ‘alternative substrate’) 12 min after the
beginning of the recirculation perfusion (Figure 8, panel A). In the series
addressing the signalling pathways (see Results section III.2.5), specific inhibitors
were added 2 min before the glucose tracer, i.e. 8 min after the start of the
recirculating phase (Figure 8). 
In both protocols, collection of radioactive coronary effluent was performed
for metabolic measurements (see section II.2.1.7 below): aliquots of 1.2 ml
coronary effluent were taken in plastic tubes before (at min 20, 25, 30, and 35 of
the recirculating period; P1 – P4 in Figure 8, panel A), and after insulin addition
(i.e. at min 38, 42, 46, and 50; P5-P8). The total duration of the perfusion
experiments (including the first non-recirculating phase) was 60 minutes.
The third and last perfusion procedure (see Figure 8, panel B) was used to
investigate the inotropic effects of isoproterenol in hearts from LPS-treated rats,
as well as direct ex vivo effects of LPS on the contractility of the isolated
hearts.These perfusions were performed with glucose as the sole substrate. 
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Figure 8: Experimental design of heart perfusions
For details: see text (section II.2.1.6).
II.2.1.7 Cardiac metabolism
II.2.1.7.1 Glucose uptake and glycolysis
Glucose uptake and glycolysis were measured as previously described [22, 36,
65] (Figure 8, panel A). Briefly, the rate of 3H2O formation from 2-[3H]-D-
glucose, and 3-[3H]-D-glucose was used to calculate the rate of glucose uptake
(i.e. transport across the cell membrane of the heart muscle cells
+ phosphorylation via the hexokinase), and glycolysis, respectively. The tracer
was added to the perfusion medium (final concentration 2µM, specific activity
10 min
Heart-
isolation
INSULIN
8 min
β-HB
14 min
End of the 
PerfusionINHIBITORS
TRACER
- P1 to P4: 15 min.
- P5 to P8: 12 min.
A.
10 min
Heart-
isolation
End of the 
Perfusion
non
recirculated
B.
t=0   t=5       t=13         t=23           t=33   t=39         t=49               t=62
 Pre-
 perfusion M1     M2          M3              M4               M5      M6              M7                   M8
.
non recirculated perfusion 
containing LPS ( 1 or 5mg/ml)
Perfusion sample collect:
- P1 to P4: 15 min
- P5 to P8: 12 min 
 Pre-
 perfusion P1      P2      P3     P4  P5    P6   P7    P8
recirculated
non
recirculated
   non
recirculated
Materials and methods                                                                                           19
2µCi /100 ml perfusate, injection volume 500 µl) at the end of the 10 min
equilibration period. The radioactive aliquots (1.2 ml of coronary effluent) were
first mixed with 120 µl of HClO4 (70 %). After centrifugation, 1 ml of supernatant
was neutralized with 405 µl KOH (3N) and 200 µl KHCO3 (1M). The samples
were centrifuged and 1 ml of the supernatant was passed over columns filled with
4 ml Dowex AG1-X8 resin, borate form (BioRad, Munich), and the tritiated water
present in the effluent was counted by liquid scintillation (see Figure 9).
Figure 9: Principle of glycolytic (and glucose uptake) measurements in perfused hearts 
Glucose is taken up across the plasma membrane via specific transporters (GLUT), then readily
phosphorylated to glucose-6-phosphate (Glu-6P, hexokinase reaction), which is then in part fed
into the glycolytic pathway, whose main rate-limiting step is the phosphofructokinase (PFK)
reaction. Because the hydrogen at the C3-atom of the glucose molecule is exchanged with water
at the triose-phosphate-isomerase (TPI) reaction, the rate of 3H2O formation from 3-[3H]-
glucose is a function the flux through the TPI, and therefore also through the PFK. Likewise,
the rate of tritiated water formation from 2-[3H]-glucose can be used to measure glucose
uptake, because the hydrogen bound to the C2-atom of glucose is exchanged onto water in the
phosphoglucose-isomerase step which follows the hexokinase-catalized formation of Glu-6P.
After a 10 minutes equilibration phase, the hearts were perfused in a recirculating mode with
Krebs-Henselheit buffer to which tritium-labelled glucose was added (3-[3H]-D-glucose);
aliquots of radioactive perfusate (coronary effluent) were taken at the time points indicated in
Figure 8 (P1-P8), and treated as mentioned in section II.2.1.7.1. These samples  were then
pipetted onto Dowex AG1-X8 borate gel columns, and eluted with water to separate non-
metabolised tritiated glucose (which binds to the resin) from the tritiated water formed in
glycolysis (or following glucose uptake). The quantity of eluted radioactive water was then
measured in a liquid scintillation counter.
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The rate of glycolysis (or glucose uptake) was determinated as follows: 
At t=32, 41 and 45 min three aliquots of radioactive perfusate were collected
to evaluate the specific activity of glucose (SA).
Under basal conditions: 
Rate of glycolysis (Rbgly)= [(b/SA)/w] • k   in µmol • min-1 • g-1with:
- b: basal slope in dpm • min-1  (see Figure 10)
- SA: specific activity of glucose (in dpm/mol): [(1000 • Φ)/x] with:
Φ = mean radioactivity in 100 µl perfusate (in dpm)
x:number of mole of glucose in 100 ml perfusate
-  w: wet weight of the heart (in g)
- k: dilution factor: 1/V with:
V: total volume of perfusate (in ml)
Figure 10: Determination of the rate of glycolysis and glucose uptake
Pi: sample n°i taken from radioactive perfusate; b: basal slope; i: slope under insulin-
stimulated conditions
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II.2.1.7.2 pH and Osmolarity 
In order to check the physiological conditions of our recirculating perfusion
system (100 ml perfusion with glucose as sole substrate in the presence of insulin)
samples (1 ml) were taken at regular intervals (5 min) for pH and osmolarity
measurements.
II.2.1.7.3 Glucose consumption and lactate formation
In parallel to the acidity and osmolarity measurements, the concentrations of
glucose and lactate were measured (see sections II.2.1.2.3 and II.2.1.2.4) over time
in coronary effluent to (non-radioactively) determine the rate of glucose
consumption and lactate formation by the isolated heart.
II.2.1.8 Action of isoproterenol in isolated hearts
The ability of the isolated hearts to respond to a β-adrenergic stimulation (in-
duced to mimic an increased sympathetic nervous system activity) was tested in
steady state conditions in Langendorff-perfused hearts (see above) by adding the
β-selective adrenergic receptor agonist isoproterenol (final concentration: 0.1 µM)
in for an observation period of 5 minutes to the perfusion medium.
II.2.1.9 Direct effects of LPS on the contractility of isolated hearts
The direct influence of LPS on the myocardial contractility was tested in vitro
by perfusing hearts isolated from (non-treated) control rats with endotoxin for
54 min with a non recirculating perfusion. The protocol was the following: after
10 min standard perfusion to reach a steady state, the hearts were submitted either
to another standard Krebs-Henselheit medium (with glucose as sole substrate), or
switched to a new perfusion containing LPS (1 or 5 mg/l). At the end of this second
phase, the hearts received a standard (LPS-free) perfusion to assess the reversibility
of detect possible LPS effects. 
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II.2.1.10 Nitrite release in recycling perfusion 
Nitric oxide formation by the heart was indirectly assessed by measuring
the nitrite oxidatively formed from NO [6]. For this purpose, 500 µl of coronary
effluent were collected from the closed system at the time points indicated in
Figure 28, and mixed 1:1 with Griess reagent, and optical absorbance was deter-
mined at 550 nm spectrophotometrically. A standard curve was constructed using
known concentrations of sodium nitrite over the linear range of the assay (0.1-
15 µM nitrite).
II.2.1.11 Myocardial inducible NO synthase (iNOS) expression
⌧ Sample preparation:
At the end of the 6 h period following intravenous application of saline or
LPS, the hearts were excised as described in section II.2.1.4, freeze-clamped in
liquid nitrogen, and stored at -80°C before being homogenised in liquid nitrogen
with a mortar and pestle. Cardiac tissue samples (frozen powder) were homoge-
nized with a pestle with 2 ml TES buffer (composition: see below) containing
0.1 mM PMSF and were subsequently sonicated (sonifier Branson, 60W 4 cycles
of 15 seconds each). The homogenates were then diluted in cold TES buffer 1:20.
The further preparation of the samples consisted of three steps: mixing 30 µl of
these diluted homogenates with 15 µl Laemmli buffer, denaturation by boiling for
2 min at 98 °C and centrifugation (500 g for 2 min).
❑ TES buffer: 250 mM Saccharose; 20 mM Tris-HCl; 
1  mM EDTA
⌧  Preparation of Kupffer cells from rat liver:
Kupffer cells from rat liver (male Sprague-Dawley, 800g body weight) were
kindly provided by Prof. A.M. Gressner (Dept. of Clinical Chemistry, RWTH,
Aachen) and were isolated according to a procedure developed in his laboratory
[161]. The isolated cells (79.6 millions) were pipetted into four Petri dishes
(diameter: 10 cm) in 15 ml medium each (see composition below) and incubated
with or without endotoxin (Salmonella typhimurium lipopolysaccharide, Sigma,
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1 µg/ml for 24h). A protein assay (see below) was used to load the equivalent of
100 mg protein on the gel.
❑ Incubation medium for Kupffer cells: RPMI 1640 (ref. F1275, Biochrom AG,
Berlin-Germany) + 10% Fetal bovine
serum (ref. 10270-106, Gibco BRL,
Karlsruhe-Germany) + 1% penicillin-
streptomycin solution (ref. P11-010, PAA
Laboratories, Linz-Austria).
⌧ Protein assay:
5 µl of the diluted heart samples were added to 1.3 ml of Dye-Reagent
(BioRad, Munich) [diluted 1:3 in water], and then assayed for protein content by
the method of Bradford [24] using gamma-globulin as the standard.
⌧ Electrophoresis and blotting:
  SDS-PAGE was performed with 100 µg protein loaded per lane on homoge-
nous gels (8.5% acrylamide; composition see below) by using a BioRad system
(ref. Miniprotean II) at a constant current of 70 mA. After electrophoresis, the
proteins were transferred to a polyvinylidene difluoride membrane (Sequi-Blot
PVDF Membrane, BioRad) for 1h at 250 mA by using a transfer buffer (25 mM
Tris, 192 mM glycine, and 20% vol/vol methanol) (see Figure 11). The membrane
was then blocked with 5% skim milk powder (wt/vol) in phosphate buffered
saline (PBS, see composition below) for 45 min at 37 °C. The blot was then
incubated at 4 °C for 12h with rabbit polyclonal antiserum to rat and mouse iNOS,
diluted 1:1000 in blocking buffer (5% wt/vol skim milk powder in PBS). The
blots were washed four times at 37°C for 10 min each in PBS containing 0.01%
vol/vol Triton X-100 and 5 min in PBS before incubation with horseradish
peroxidase-conjugated goat anti-rabbit IgG (Sigma, Munich) diluted 1:1000 with
blocking buffer for 1h at room temperature. After that the blots were washed twice
for 3 min each in PBS containing 0.05% vol/vol Triton X-100 and three times for
5 min in PBS. All of the membrane processing was done under constant agitation.
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Solutions used for SDS-PAGE electrophoresis:
❑ Stacking gel: 5% (w/v) Acrylamide; 0.13% (w/v)
Bisacrylamide; 0.125 M Tris-HCl; 0.1%
(w/v) Ammonium persulfate; 2.2 M
TEMED (pH 6.8 at room temperature)
❑ Separating gel: 8.5% (w/v) Acrylamide; 0.22% (w/v)
Bisacrylamide; 0.375M Tris-Base;0.043%
(w/v) Ammonium persulfate; 2.2 M
TEMED (pH 8.8 at room temperature)
❑ Laemmli sample buffer: 60% (v/v) Glycerol; 3.3 M Tris-HCl; 6%
(v/v) SDS; a drop of Bromphenol-blue (pH
6.8 at room temperature)
❑ Electrode buffer: 1.91 M Glycine; 1% (w/v) SDS; 250 mM
Tris-Base
Solutions used for blotting:
❑ PBS: 134 mM NaCl; 2.6 mM KCl; 6.4 mM
Na2HPO4; 1.46 mM KH2PO4 (pH 7.4 at
room temperature)
❑ Transfert buffer: 192 mM Glycine; 20% (v/v) Methanol; 
25  mM Tris-Base
❑ Gel stainning solution: 7.5% (v/v) vinegar; 25% (v/v) Isopropanol;
0.05 (w/v) Brilliant blue R
❑ Blocking buffer: PBS + 5% (w/v) fat low milk (as for
antibody solution)
❑ Wash buffer: PBS + 0.01% (w/v) Triton X-100
⌧ Silver staining:
      The protein bands detected by the antibodies were visualised using the rea-
gents from an enhanced chemiluminescence detection kit (Amersham,
Braunschweig) and were autoradiographed using scientific imaging film (Kodak). 
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Solutions used for staining:
❑ Stop solution: 12% (v/v) vinegar; 50% (v/v) ethanol
❑ Developer: 0.57 M Na2CO3; 16 µM Na2S2O3; 0.05%
(w/v) formaldehyde
Figure 11: ”Sandwich“ arrangement for the blotting of electrophoretically separated proteins
to the nylon membrane.
II.2.1.12 Preparation of heart extracts for metabolite measurements
At the end of the 6 h period following intravenous application of saline or
LPS, the hearts were excised as described in section II.2.1.4, freeze-clamped in
liquid nitrogen, and stored at -80°C before being homogenised in liquid nitrogen
with a precooled mortar and pestle. The resulting heart tissue (in form of powder)
was used to determine the metabolite concentration (see following sections).
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II.2.1.13 Cardiac content of high energy phosphates
Cardiac tissue samples (400 mg powder) prepared as above were first
treated with 0.3 N ice-cold perchloric acid (2ml) and centrifuged at 3000 g for
5 min at 4°C. The supernatants were neutralised with KOH 3N to ~ pH 7.5. After
15 min the extracts were centrifuged at 13000 g for 5 min at 4°C to remove the
KClO4. The dry weight was determined with 100 mg of heart sample (powder in
an incubator for 2 days at 100°C) was used together with the wet weight to cal-
culate the dilution factor. Energy-rich phosphates (ATP, ADP, creatine phosphate)
were measured in the supernatants by high-performance liquid chromatography as
described [67]. 100 µl of each supernatant sample was injected into the HPLC and
the content (δ) of the different adenylates (in nanomol) was determined by
integration of the area surfaces provided by HPLC profiles at the corresponding
elution times.
Determination of the final concentration (Cf) used dry weight (100 mg heart tissue
at 100 °C for 2 days) and calculation of the dilution factor (f) after Griese [55].
Thus :
Cf (in µmol/g wet weight) = f • C0 with:
C0=δ/100 (in µmol/ml)
II.2.1.14 Cardiac glycogen content
100 mg of heart tissue (powder) was taken and glycogen content was deter-
mined using an alkaline extraction method and enzymatic assay [77]. Protein
denaturation in 100 mg and 2 ml water 100 °C during 5 min, cooling on ice and
sonicated (sonifier Branson, 60W 4 cycles of 15 seconds each). From this
resulting sample, 0.5 ml was used for determination of free glucose concentration
(extract 1), and 0.5 ml for the glycogen concentration (extract 2).
Extract 1 was added to HCLO4 3N (0.05 ml) and centrifuged (10000 g for
15 min). 0.05 ml of the supernatant was added to 1ml ATP-buffer (see
composition in [77]) and set to zero. After addition of 0.01 ml hexokinase
suspension (1500U/ml) OD was recorded at 340 nm and after 3 min ∆ELwas
determined.
Extract 2 was added to 1 ml amyloglycosidase (7.4 U/ml) for digestion in
water bath 40 °C for 2 hours, then added to 0.1ml HCLO4 3N, neutralised with 0.1
ml KHCO3 and finally centrifuged (10000 g for 15 min). 0.1ml of supernatant was
submitted to the same measurement as supernatant of extract 1 to obtain ∆EH.
The glycogen concentration of each cardiac sample Qi (in µmol/g wet weight) was
determined after Keppler and Decker [77]:
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Qi.= (10.67∆EH - 3.5∆EL) • fi
with fi: dilution factor corresponding to each sample (i)
II.2.1.15 Cardiac citrate content
Heart citrate content was assessed using the method described by S. Dagley
[33] with minor modifications. Briefly, 500 mg heart tissue sample (powder) were
mixed with 3 ml ice-cold HClO4, sonicated, centrifuged, neutralised to pH 7.0-7.6
with KOH 6N and filtered.
0.1 ml of this filtered sample solution was added to 1 ml
ZnCl2/Triethanolamine-buffer (0.1 M TRA, pH 7.6; 0.2 mM ZnCl2) and 10 µl
NADH solution (10 mM) in a cuvette to determine the optical extinction value E1
at 340 nm reflecting the totality of NADH.
Pyruvate and oxalate contents (results not used) in the sample were
determined after addition of 20 µl of the mixture Lactate dehydrogenase (LDH)/
Malate dehydrogenase (MDH) and reading the extinction value E2.
The LDH/MDH mixture contained :
- 400 µl LDH suspension (in ammonium sulfate) 2750 U/ml
- 300 µl MDH suspension (in ammonium sulfate) 6000 U/ml
Citrate content was calculated from the extinction value E3 read after addition
of 20 µl of citrate lyase (CL) 120 U/ml using the following formula:
Cs: Concentration citrate in the sample: [(Q • V/v)/P] in nmol • g-1 wet weight
with:
Q: Quantity of citrate in the cuvette = NADH consumed
= [(E2-E3)/KNADH] • 1000 (in µM)
with KNADH: extinction coefficient of NADH at 340 nm = 6.22/mM
with  V: volume of heart extract (in ml HClO4), here 3 ml
v: volume of filtered sample solution (in µl), here 100 µl
P: wet weight of heart tissue, (in g) here 0.5 g
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II.2.2 Experiments with isolated cardiomyocytes
II.2.2.1 Glucose metabolism
II.2.2.1.1 Cell isolation
The isolation of cardiomyocytes for metabolic analyses was carried after a
procedure developed in our laboratory [45]. Briefly, after excision and fixation to
the Langendorff set-up (see section II.2.1.4 above, Figures 12 and 13), the rat
heart was first perfused with a calcium free buffer (medium A) at 37° C and then
with recirculating collagenase solution or medium B (Wako, Japan, ref. 034-
10533, lot PAJ 7290, 187 units/mg) for an additional 20 minutes. Ten min after
the beginning of the enzyme perfusion a two step recalcification was carried out to
reach 0.2 mM Ca2+. Finally the heart was removed from the perfusion apparatus,
the auricles were cut and the heart ventricles were disrupted with tweezers. The
heart tissue was transferred into a glass beaker and placed in a shaking water bath
(37°C) to disperse the cells. The dispersed myocytes were filtered on a nylon
mesh (200 µm), centrifiged for 1 min at ~ 800 g, and resuspended in wash buffer
(medium D). The isolated ventricular myocytes were stored for 1 hour on a rotary
shaker.
Following the incubation in medium D, the freshly isolated cardiomyocytes
were washed twice in medium E containing 5 mM glucose and resuspended in
16 ml of the same buffer. The composition of the buffers are all available in [45].
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Figure 12: Perfusion setup (Langendorff) used for cardiomyocytes isolation.
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Figure 13: Schematic representation of the perfusion setup (Langendorff) for
cardiomyocytes isolation
The rat hearts were isolated and fixed to the aortic cannula (Ca) and first perfused with a
physiologic buffer (PB) bubbled with oxygen. Syringes (Sr) were used to dispel gas bubbles out
of the perfusion system. After three min, the valve (V) was used to switch on the enzyme
perfusion. The collagenase buffer (Col) was recirculated through a peristaltic pump (PP).
During the whole duration of the perfusion, the hearts were kept in a thermostated perfusion
chamber (PC). For further details: see text.
II.2.2.1.2 Protein assay
The protein assay was carried out according to Bradford´s [24] which is based
on the observation that Coomassie Brilliant Blue G-250 exists in two different
colour forms, red and blue. The red form is converted into the blue form upon
binding of the dye (alkaline commercial coloured solution) to protein (with good
colour stability for 1 h). This reaction causes a shift in the absorption maximum of
the dye from 465 to 595 nm. The increase in absorption monitored at 595 nm is
proportional to the protein concentration.
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 Two aliquots of 400 µl were collected from 10 ml cell suspension in
Eppendorf tubes and centrifuged for 1 min (at ~ 1000 g). The supernatants were
discarded and the pellets resuspended with 1 ml of isotonic NaCl-solution. After a
thorough mixing by vortexing, the samples were submitted to another
centrifugation, and the pellets were stored at -80° C for the protein analysis.
After thawing at room temperature, the pellets were resuspended in 1 ml NaOH
(0.1M) and sonicated on ice (sonifier Branson, 60W/ 6 cycles of 15 seconds each)
BSA (bovine serum albumine) solutions (1 to 20 mg/ml) were used for standard
curve.
In each plastic cuvette (10x4x45mm) were placed:
- 1.3 ml of Dye Reagent (diluted 1:5 in water),
- 5 µl of cell sample.
After a gentle mixing of the cuvette, the measurement of the sample extinction
was made in duplicate against a reagent blank with a spectrophotometer at 595 nm
and the protein content of each sample calculated using the standard curve.
II.2.2.1.3 Gylcolytic measurement
To determine the glycolytic rate of cardiomyocytes the same principle as for
the isolated hearts was used (see section II.2.1.7.1), but adapted to isolated heart
cells. Briefly, following the last treatment described in section II.2.2.1.1, samples
of 1ml of heart cell suspension each were placed into closed plastic vials (15 ml)
in a shaking water bath (37 °C) at successive time intervals with the additions
mentionned in section II.2.2.1.4. After the corresponding incubation time (see
section II.2.2.1.4.), 1.2 ml of the radioactive aliquots were pipetted out from the
plastic vials added to HClO4 and finally treated exactly as described in section
II.2.2.1.4 .
The glycolytic rate for isolated cells was determined as follows:
Under basal conditions:
Rb= [(R/(x • F)] • y • 2 (in nmol • h-1 • mg protein) 
with:
R: Radioactive water produced by 1mg protein (in dpm • mg-1)
x: radioactivity in 50 µl of tracer = 324260 dpm
y: concentration of glucose (in nmol/ml), here 5000 nmol/ml
F: dilution factor, here 0.566
32                                                                                          Materials and methods
II.2.2.1.4 Effect of LPS incubation in vitro on glycolysis
The effect of LPS in vitro on isolated cardiomyocytes was tested under three
different conditions:
⇒ condition 1: with glucose as sole substrate / LPS incubation: 60 min.
⇒ condition 2: with two substrates (glucose and β-hydroxybutyric acid) /
LPS incubation: 60 min.
⇒ condition 3: with two substrates / LPS incubation: 120 min.
One ml of cell suspension (prepared as described above in buffer A and
corresponding to ~ 3 mg protein; see section III.2.6) was placed in plastic vials in
a shaking water bath (37 °C) at the beginning of the experiment. Addition of LPS,
substrate (β-hydroxybutyric acid), insulin, and other biochemicals was made as
follows:
Additions:
LPS: 1 µg/ml at time = 0 min
Indomethacin: 1 µM at time = 0 min
β-hydroxybutyric acid: 3 µM at time = 20 min.
Insulin: 33 nM at time = 30 min
3-3H-D-glucose: 0.15 µCi/ml cell suspension at time = 60 min. (conditions 1 and 2)
or time = 120 min (condition 3)
The rate of glycolysis was then measured over a period of 30 min, as described
above.
II.2.2.2 Patch-clamp analyses
Inward calcium currents were measured in freshly isolated rat cardiomyocytes
by the patch clamp technique in the whole cell configuration [60].
II.2.2.2.1 Patch clamp setup
As shown in the patch clamp equipment (Figures 14 and 15) was located in a
room isolated from environmental disturbances. The patch clamp analyses were
carried out at room temperature on a vibration absorbing table surrounded by a
Faraday cage.
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Figure 14: Patch clamp setup in the Institute of Physiology (RWTH Aachen, Germany)
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Figure 15: Simplified representation of the patch clamp set-up 
The patch clamp setup included an inverted light microscope (Mi), and a micromanupulator
(MM), disposed on a vibration absorbing table (Ta). The bad chamber was illuminated by a
light source (Lt) and supplied with TEA buffer coming from storing syringes (Sr) through a
tubing system (Ts). All debris could be evacuated out of the bad chamber via a waste tube (Wt).
The bad chamber was protected from electric disturbances by a copper shielding (Sh) and the
Faraday cage (FC). The computer, the patch amplifier and the keyboard for controlling the
micro-manipulator were disposed outside of the cage.
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II.2.2.2.2 Cell isolation
For unknown reasons, the cardiomyocytes obtained using the isolation
procedures established by previous investigators [45, 75, 89] turned out to be
unsuitable for use in patch-clamp studies. Therefore an alternative method had
first to be developed. Although many protocols for separating mammalian heart
cells have been published in the literature since the 1970´s, the isolation of viable
cardiomyocyte is still a difficult exercise especially because:
- in heart tissue the muscle cells are firmly connected to each other via gap
junctions;
- the cardiomyocytes are easily damaged by mechanical impact.
Considering our own experience in cardiomyocytes isolation and all the
available information taken from the literature, we started a series of preliminary
experiments in order to obtain a good yield of calcium-tolerant cells able:
- to be viable in TEA buffer,
- to show an intact morphology,
- to be analysed by the patch-clamp technique.
Starting from the method developed by Y. Fischer [45], we modified:
- the collagenase (type, charge) and its concentration (or activity),
- the albumin concentration in the isolation media (which should protect the
separated viable cells from the proteases released from damaged cells),
- some physiological buffers,
- the duration of each step of the collagenase digestion.
Hearts were excised and placed for about 1 min into a glass beaker containing
cold Krebs-Ringer buffer n°1 (see below) before being cannulated and
retrogradely perfused through the aorta for 3 min at 37 °C with the calcium-free
buffer (KR n°2). The hearts were then perfused with the enzyme buffer for 18 min
(composition: see below). Recalcification (to 0.2 mM) was done stepwise after
another 5 and 10 min, respectively. Following this enzyme digestion the hearts
were taken off the cannula and placed in a watch-glass containing enzyme buffer.
The atria and the blood vessels were removed before the ventricles were
mechanically dissociated for 5 min in a solution containing 7 ml enzyme buffer
and 14 ml shaking buffer (see below). All the solutions were bubbled with 100%
O2. Myocytes were minced and filtered through a nylon mesh. The cells were then
resuspended in 5-10 ml Tyrode containing 1mM Ca2+ before beginning the last
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steps of recalcification from 1 to 1.8 mM. Each of the 4 recalcification steps was
carried out as follows:
- centrifugation (30 sec at 800 g);
- rapid removal of supernatant (using a vacuum pump) to eliminate dead cells;
- resuspension in Tyrode and incubation at room temperature for 5 min on a
rotary shaker.
Finally, the cell suspension was collected in a 50 ml plastic tube with
saturated O2 atmosphere and placed on a rotary shaker for a gentle agitation.
100 µl of the cell suspension (out of a total volume of 8 ml) was used for the cell
counting. The cells counts were performed in a Neubauer chamber after staining
with Trypan blue (0.4%). Only , quiescent, morphologically intact (i.e. rod-
shaped) myocytes with clear cross-striations were selected for
electrophysiological measurements. Experiments were performed at room
temperature (20-22 °C).
As shown in Table 1, the new isolation procedure described above (using the
Sigma collagenase, ref. C-9263) was the only one which provided heart ventricle
cells resistent to TEA and able to be patched relatively easily. 
Table 1: Comparison between different myocytes isolation procedures
Data are means ± SEM. Numbers in parentheses indicate number of hearts used for each
isolation procedure.
Isolation for
metabolic analyses
(collagenase WAKO)
Isolation for patch
clamp analyses
(collagenase
WORTHINGTON)
Isolation for patch
clamp analyses
(collagenase SIGMA)
Heart wet weight (g) 1.24 ± 0.02 (3) 1.23 ± 0.04 (4) 1.25 ± 0.02 (4)
Isolated cells 
(million/g heart )
2.320 ± 0.14 (3) 0.977 ± 0.08 (4) 0.887 ± 0.02 (4)
% viable cells
(colored by Trypan
blue)
68 ± 4 (3) 57 ± 2 (4) 54 ± 1 (4)
Patch ability NO Bad (leak current) YES
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Solutions used for cell isolation (adapted for patch clamp analyses):
❑ Calcium free Tyrode: 120 mM NaCl; 20mM Glucose, 20 mM Taurine,
5.4 mM KCl; 5 mM MgSO4; 5 mM Pyruvate; 10
mM HEPES (pH 7.4 at room temperature)
❑ Krebs-Ringer buffer n°1: 70 mM Saccharose; 35 mM NaCl; 25 mM
NaHCO3; 16 mM NaHPO4; 10 mM Glucose; 10
mM HEPES; 4.8 mM KCl; 1.2 mM KH2PO4 (pH
7.4 at room temperature)
❑ Krebs-Ringer buffer n°2: KR buffer n°1 + 30 mM Butane-dione monoxime
(BDM) (pH 7.4 at room temperature)
❑ Enzyme buffer: 35 ml KR n°1 + 10 mg collagenase SIGMA (ref.
C9263) + 10 mg BSA (Boehringer, fraction V
ref. 735086) (pH 7.55 at room temperature
adjusted with NaOH) 
❑ Buffer S: 128 mM NaCl; 10 mM HEPES; 6 mM KCl; 5.5
mM Glucose; 2 mM Pyruvate; 1.4 mM MgSO4 1
mM; Na2HPO4; 0.2 mM NaH2PO4 (pH 7.4 at
room temperature)
❑ Shaking buffer: Buffer S + 0.5% BSA + 200 µM CaCl2  + 15 mM
BDM 
II.2.2.2.3 Cell treatment
The protocol and the concentration of the various biochemicals used are
summarised in Figure 16. Heart cells
isolation
Addition of LPS (1µg/ml)
and inhibitors End of the experiment
Collagenase
60 min
M easurement of
 Ca2+ inward currents
Heart isolation
60-120 min 120 min60 min
buffer: TEA
Incubation
Tyrode solution
(1.8 mM CaCl2)
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II.2.2.2.4 Measurements of currents through calcium
channels
High-threshold calcium current (ICa) in Ca2+-tolerant rat ventricle myocytes
using the patch-clamp technique. A drop of cell suspension was placed on glass
coverslips in a Plexiglas chamber mounted on the stage of an inverted microscope
(Axiowert S100, Zeiss GmbH, Jena Germany) and superfused via a micro-injector
with Tyrode solution (see Figure 17). 
Patch pipettes were pulled from borosilicate glass capillary tubes with a two-
stage puller and fire-polished to a final resistance of 3-5 MΩ when filled with
pipette solution. The myocytes were voltage clamped at a holding potential of
-70 mV. 
High-giga-ohm seals (obtained by gentle suction near the center of the
myocyte) and whole cell voltage clamp [60] were obtained after superfusion of the
chamber with the external TEA buffer to replace Tyrode solution. After
establishment of the whole cell configuration, ICa,L was recorded by eliciting a
voltage pulse (200 ms) to +10 mV. The current-voltage (I-V) relationship was
assessed by measuring currents at voltage pulses (200 ms) from -80 to +60 mV
applied in 10 mV increments every 1s. Cell membrane capacitance and series
resistance were compensated by the capacitance and series resistance
compensation circuit of the patch-clamp amplifier (model EPC9, Heka GmbH,
Lambrecht, Germany). The output of recording was filtered at 1 kHz to reduce
high frequency noise.
The experiments were conducted within 2 hours after at room temperature.
The amplitude of ICa was calculated as the difference between the peak inward
current and the current measured at the end of the test pulse, and its density was
obtained by dividing ICa amplitude by the membrane capacitance.
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Figure 17: Simplified representation of the bath chamber
The cardiomyocytes were placed into a bath chamber (BD), mounted on an inverted light
microscope (Mi) containing TEA buffer. 
Ts: tubing system; IN: micro-injector. Re: reference electrode; Te: micro-pipette containing
buffer and the tension pipette.
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Solutions used for patch clamp analyses:
❑ Bath buffer: 136 mM TEA; 10 mM HEPES; 2.2 mM
MgCl2; 1.8 mM CaCl2 (pH adjusted to 7.4
at room temperature with TEAOH, and
stored at 4°C)
❑ Pipette buffer: 140 mM CsCl2; 10 mM HEPES; 10 mM
EGTA; 2 mM MgCl2;; 0.3 mM ATP (pH
adjusted to 7.2 at room temperature with
CsOH, filtered and stored at -18°C)
II.3 Statistical analysis
Values from control and endotoxin groups were compared using a one-tailed
Student´s t-test for unpaired data. For multiple comparisons one-way analysis of
variance was used, where indicated. All values were expressed as means ± SEM,
and P values < or = 0.05 were considered as statistically significant.
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III Results
III.1 Model validation
In a first series of experiments, a previously described protocol of endotoxin
treatment was used to induce a generalised inflammatory reaction coupled with a
cardiac depression (intraperitoneal administration of 0.5 mg lipopolysaccharide
from Salmonella typhimurium [99]). However, in our laboratory, the occurrence
and degree of contractile depression observed ex vivo (i.e. in perfused hearts
isolated 6 hours after the LPS injection) turned out to be highly variable. The fact
that this protocol is prone to variability was subsequently confirmed by Prof. X.
Meng (Denver, USA; personal communication), a leading expert in the field. We
therefore tried out several modifications to this protocol and found that
intravenous application of LPS from S. typhimurium (1 mg/kg BW) into the
caudal vein caused a very reproducible systemic inflammatory reaction, as well as
changes in cardiac function, as detailed below. 
III.1.1  Rectal temperature
In 24 rats, rectal temperature was examined before and 6 hours after
administration of endotoxin or saline vehicle. The baseline body temperature was
37 ± 0.05 °C for the control and 37.1 ± 0.06 °C for the LPS-treated rats. Compared
to control injection of non lethal dose of LPS caused a significant increase of this
parameter by 0.6 oC (see Figure 18).
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Figure 18: Effect of LPS on the body temperature
The rectal temperature of rats was measured under ether  anaesthesia at time 0 and 6 h using
an electronic thermometer. Date are means ± SEM from 12 rats in each experimental group.
 ***: P < 0.001 versus control (unpaired t-test). 
III.1.2 Animal behaviour
As early as 60 minutes after the intravenous injection the LPS-treated rats
showed first symptoms of a generalised diseased state, including a characteristic
piloerection, hypokinesis and diarrhoea.
III.1.3 Blood analyses
The LPS-treatment resulted in metabolic, hormonal and haematological
disturbances which are summarised in Table 2.
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Table 2: Effects of LPS on hematological, metabolic and hormonal parameters
The rats received an intravenous injection of LPS (S. typhimurium, 1 mg/kg), or an equivalent
volume of an isotone saline vehicle (control). 6 hours later the rats were anaesthetised and
blood samples were taken . Numbers in parentheses indicate numbers of animals in each group.
n.s.: not significant; ** : P < 0.01; ***: P < 0.001 versus control (unpaired t-test).
Control
(saline vehicule)
LPS-Injection P 
(t-test)
Partial
thromboplastin-time (s)
13.2 ± 0.38 (6) 25.5 ± 1.3 (6) ***
Platelets (105/µl) 779 ± 16 (3) 432 ± 37 (4) ***
Leukocytes (103/µl) 16.0 ± 0.6 (3) 6.2 ± 0.2 (4) ***
Red blood cells
(106/µl)
8.3 ± 0.02 (3) 8.0 ± 0.13 (4) n.s.
[Glucose] Serum
(mg/dl)
187.4 ± 4.8 (5) 213.5 ± 9.8 (4) **
[Lactat] Serum (mMol/l) 1.88 ± 0.17 (5) 4.7 ± 0.27 (4) ***
[NEFA] Serum
(mMol/l)
0.40 ± 0.06 (5) 0.75 ± 0.12 (4) ***
[Insulin] Serum (µg/l) 3.0 ± 0.09 (5) 24.0 ± 1.1 (5) ***
[Cortisol] Serum (nMol/l) 4.82 ± 0.49 (5) 5.90 ± 0.37 (4) n.s. (0.07)
Hematocrit (%) 47.8 ± 0.7 (3) 50.4 ± 1.5 (4) n.s. 
Thus, the cell counts of platelets, and leukocytes were reduced to 55% and
38% of control levels, respectively. This was accompanied by a doubling of the
PTT-time, which is characteristic of a decreased coagulation potential, and is
likely to be the consequence of the thrombopenia. The hematocrit value was not
significantly altered.
The plasma levels of the energy substrates glucose, lactate, and fatty acids
rose significantly, and in the case of the latter two, very substantially, which is
indicative of a general fuel mobilisation. At the same time, the plasma
concentration of the stress hormone cortisol tended to increase, although this
effect did not quite reach statistical significance (perhaps due to the fact that the
anaesthesia itself already induces the cortisol production in rats).
Finally, the plasma level of insulin was dramatically increased. Since, at the
same time, glycemia was not decreased – but even elevated, as mentioned above –
this hyperinsulinemia indicates a state of pronounced insulin resistance.
44                                                                                                                   Results
All these changes (e.g. thrombopenia, fuel mobilisation, and insulin resistance) are
in agreement with previous reports on generalised inflammation or stress
reactions, and thus prove the reliability and reproducibility of the experimental
protocol used.
III.1.4 Cardiodepression ex vivo
Preliminary experiments demonstrated that cardiac function was not
influenced by saline injection (as compared to hearts from non-treated animals;
not shown). In other words, the first anaesthesia and injection procedure had per
se no effect on the functional behaviour of hearts isolated 6 h later. 
The effect of LPS on the contractility of the left ventricle in rats is illustrated
in Figure 19. Intravenous administration of 1 mg/kg LPS induced a reproducible
contractile depression that could easily be detected ex vivo. Thus, the left
ventricular developed pressure (LVDP) was 47 ± 6 mm Hg in hearts isolated from
LPS-treated rats vs. 92 ± 4 mm Hg in saline controls (Figure 20). Contraction and
relaxation velocities (+dP/dt, -dP/dt) were also significantly reduced (from
2867 ± 110 to 2027 ± 120 , and 2440 ± 73 to 1680 ± 82 mm Hg/sec, respectively).
In addition, the coronary flow was lower than in controls, while the heart rate
remained unchanged (Table 3). However, the diminished coronary flow is likely
to be the consequence rather than the cause of the mechanical dysfunction because
perfusion with the nitric oxide donor and vasodilator SNAP (S-Nitroso-N-
Acetylpenicillamine, 50 µM) increased coronary flow by 64% without improving
ventricular contractile function (not shown).
Figure 19: Qua
hearts (ex vivo
SControllitative illustration of the depressed ven
) following LPS treatment in vivoLPtricular contractility of isolated rat
25 mm Hg
2 min
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Figure 20: Quantitative effect of LPS on left ventricular developed pressure (LVDP) of
isolated rat hearts
6 hours after saline (control) or LPS injection (LPS) the hearts were isolated and perfused
(Langendorff modus) with Krebs-Henselheit buffer containing glucose (5.6 mM) as sole
substrate. LVDP was measured in steady state (10 min after the beginning of the perfusion) as
indicated in section II.2.1.5. Data are means ± SEM from 15 rats in each experimental group.
***: P < 0.001 versus control (unpaired t-test).
Table 3: Effect of LPS in vivo on the physiologic functions of isolated hearts in vitro
6 hours after saline (control) or LPS injection (LPS) the hearts were isolated, perfused
(Langendorff modus). Left ventricle developed pressure (LVDP), coronary flow and heart rate
were recorded in steady state. Data are means ± SEM. n.s.: not significant;
***: P < 0.001 vs. control (unpaired t-test). The numbers in parentheses correspond to the
numbers of the hearts investigated in each experimental group.
Control
(saline vehicle)
LPS injection P
(t-test)
LVDP(mmHg) 92 ± 4 (11) 47 ± 6 (14) ***
Coronary flow
(ml/min)
14.6 ± 0.4 (11) 10.4 ± 0.3 (14) ***
Heart rate
(beats/min)
250 ± 7 (11) 254 ± 9 (14) n.s.
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III.1.5 pH and osmolarity
During all the perfusion period the pH and osmolarity of the Krebs-Henselheit
medium remained stable, i.e. in the range of 7.4 and 300 mOsm, respectively.
III.1.6 Glucose consumption and lactate formation
The glucose uptake and glycolysis measurements made using radioactive
glucose tracers were validated with non-radioactive methods. For this purpose,
(i) glucose consumption (which is largely limited by glucose uptake) was
determined by monitoring the disappearance of the sugar in the perfusion medium,
and (ii) lactate formation (which is an indirect measure of glycolysis) was
quantified. 
The absolute rates of glucose consumption (in the presence of 17 nM insulin)
are comparable to those determined using the 2-3H-D-glucose tracer (Table 5). In
addition, this series confirms that there is no difference between the both
experimental groups under these conditions (Figure 21). The calculation of the
rate of glucose metabolised to lactate does not reveal an LPS effect on glycolysis
either  (Table 5). 
Note that the relatively high percentage of glucose ending up as net
extracellular lactate in both experimental groups is not necessarily a sign of an
impaired oxidative (i.e. mitochondrial lactate or pyruvate oxidation) metabolism
in this perfused heart model, because the fate of glycolytic lactate also depends on
the extracellular lactate concentration. Thus, in the absence of added (exogenous)
lactate, glycolytic lactate will leave the cardiac cells by virtue of the mass action
ratio of the lactate dehydrogenase reaction and lactate transport across the cell
membrane. 
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Figure 21: Changes in glucose and lactate concentration in the recirculating perfusion
medium
6 hours after endotoxin (LPS) or saline injection (control) the hearts were isolated and perfused
with glucose as sole substrate (in the presence of 17 nM insulin) as described in section II.2.1.4.
During the recirculating perfusion phase the concentration of glucose and lactate in the
medium were measured using enzymatic methods (see sections II.2.1.2.3. and II.2.1.2.4).
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Table 4: Rates of glucose consumption and lactate production in hearts perfused with
glucose as the sole substrate
Data are means ±  SEM. n.s.: not significant (unpaired t-test). Numbers in parentheses indicate
number of investigated hearts. For further details: see legend of Figure 21.
Control LPS P (t-test)
Lactate production 
(µmol • min-1 • g-1) 1.04 ± 0.16 (3) 0.98 ± 0.15 (3) n.s.
Glucose uptake 
(µmol • min-1 • g-1) 0.94 ± 0.18 (3) 0.85 ± 0.03 (3) n.s.
Glucose metabolised into
lactate (%) 44.5 ± 1.8 (3) 44.2 ± 4.5 (3) n.s.
III.2 Effect of LPS on cardiac glycolysis and glucose uptake 
III.2.1 With glucose as sole substrate
Using the inflammatory model described above, we investigated if the LPS-
treatment could lead to measurable ex vivo changes in cardiac glucose utilisation.
In a first series of experiments, we perfused the isolated hearts with glucose
(5.6 mM) as sole substrate, and measured the rate of glucose uptake and
glycolysis (see section II.2.1.7). As shown in Table 7, we could not notice any
reductions of these metabolic rates in the LPS group in these conditions with the
exception of the insulin-stimulated rate of glucose uptake which increased from
1.00 ± 0.04 to 1.23 ± 0.06 µmol/g/h.
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Table 5: Effect of the LPS treatment in vivo on the glucose uptake and glycolysis
 of isolated hearts  (glucose as sole substrate)
6 hours after saline (control) or LPS injection the heart were isolated and perfused
(Langendorff modus). The basal or insulin-stimulated rate (17 nM insulin) of glucose uptake
(time dependent production of 3H2O from 2-3H-D-glucose) and the glycolytic rate (formation of
3H2O from 3-3H-D-glucose) were calculated as mentioned in ”Methods“. n.s.: not significant;
**: P < 0.01 versus control (unpaired t-test). The respective numbers of investigated hearts are
in parentheses.
Control
(saline vehicule)
LPS-injection P
(t-test)
Basal glucose uptake
(µmol • g-1 • min-1)
0.32 ± 0.03 (4) 0.25 ± 0.04 (4) n.s.
Insulin-stimulated
glucose uptake
(µmol • g-1 • min-1)
1.00 ± 0.04 (4) 1.23 ± 0.06 (4) **
Basal Glycolysis 
(µmol • g-1 • min-1)
0.28 ± 0.03 (5) 0.22 ± 0.03 (9) n.s.
Insulin-stimulated
Glycolysis
(µmol • g-1 • min-1)
0.73 ± 0.06 (5) 0.71 ± 0.05 (7) n.s.
III.2.2 In the presence of 2 substrates (glucose + β-hydroxybutyric
acid)
As shown in Table 2 the insulinemia of LPS-injected rats was dramatically
increased (8-fold) – whereas glycemia was only modestly elevated (which are
clear signs of a systemic insulin resistance) – and the serum concentration of non-
esterified fatty acids almost doubled. It is well-established that cardiac (and
muscle) glycolysis and glucose utilization are inhibited in situations of increased
availability of alternative fuels, such as fatty acids or ketone bodies (which is part
of the so-called glucose-fatty-acid cycle, or Randle cycle [119]).
We therefore sought to simulate these in vivo conditions by perfusing the isolated
hearts with β-hydroxybutyrate in addition to glucose. As illustrated in Figure 22,
the presence of β-HB in the perfusion induced a small reduction of the glucose
uptake in both experimental groups in the same manner but did not reveal a
specific LPS-dependent impairment of this metabolic step under basal as well
under insulin stimulated conditions.
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As expected the addition of the ketone body to the perfusion medium
provoked a significant decrease of the glycolytic rate (see Figure 23) in hearts
from saline and LPS-treated rats. Of interest, these reduction of the glycolysis
induced by the alternative fuel β-HB is clearly stronger in the LPS group,
especially under insulin-stimulated conditions. Thus the glycolytic rate of the
LPS-treated hearts was reduced by 57% (basal) and 77% (insulin) while in the
controls only a reduction by 44% and 54% was recorded, respectively. This new
observation is indicative of an effect of LPS on the substrate competition.
Figure 22: Effects of LPS treatment in vivo on the glucose uptake of isolated hearts perfused
with glucose and β-hydroxybutyric acid
6 hours after  saline (control) or LPS injection (LPS) the hearts were isolated and perfused
(Langendorff modus) with glucose (5.6 mM) and β-hydroxybutyric acid (5mM) as indicated in
the legend (of the figure). Basal and insulin stimulated glucose uptake was measured as
described in ”Methods“ . **: P < 0.01 vs. corresponding control (unpaired t-test). Data are
means ± SEM from 4 hearts.
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Figure 23: Influence of LPS treatment (in vivo) on the glycolysis of isolated hearts (perfused
with 2 substrates: glucose and β-hydroxybutyric acid)
6 hours after  saline (control) or LPS injection (LPS) the hearts were isolated and perfused
(Langendorff modus). as indicated in the legend (of this figure) The basal or insulin stimulated
glycolytic rates were calculated as mentioned in „Methods“. n.s.: not significant; **: P < 0.01
versus corresponding control (unpaired t-test). Data are means ± SEM from 5-9 hearts.
III.2.3 Influence of LPS on cardiac citrate content
In muscle and heart, the reduction of metabolic flow through the
phosphofructokinase (PFK) reaction – a major rate-limiting step of glycolysis – by
alternative fatty-acids and ketone bodies has been explained by an increase in the
cellular content of citrate, which allosterically inhibits both PFK-1 and PFK-2
[38]. 
The results corresponding to the measurements of citrate concentration in
heart extracts are presented in Figure 24. In the control group, addition of
β-hydroxybutyric acid into the perfusion induced a 2.3-fold increase of the cardiac
citrate concentration when compared to the value obtained upon perfusion with
glucose as the only substrate (0.63 vs. 0.28 µmol/g wet weight). This is in line
with previously reported observations [79].
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In hearts from the LPS group, the citrate content measured at the end of a
perfusion with glucose alone was the same as in controls (Figure 24). However, in
the presence of β-hydroxybutyrate, there was a 3-fold higher level of cardiac
citrate, i.e. about one third higher than in controls under the same conditions
(Figure 24). Therefore, it is conceivable that a larger gain in cellular citrate may
be responsible for the stronger glycolytic inhibition by β-hydroxybutyrate in
hearts from the LPS group.
Figure 24: Effect of LPS on β-hydroxybutyric acid-induced changes in cardiac citrate
content in vitro
6 hours after the hearts were isolated and perfused as indicated in the legend. After a 40 min.
perfusion with one (glucose) or two substrates (glucose + β-hydroxybutyric acid), with the 15
last minutes in presence of insulin, the hearts were frozen and their citrate content measured
(see ”Methods“). ***: P < 0.001 vs. corresponding control (unpaired t-test). Data are means ±
SEM from 3-4 hearts.
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III.2.4 Influence of LPS on cardiac glycogen content
In view of the more pronounced depression of glycolysis by
β-hydroxybutyrate in LPS hearts (see section III.2.2) without a decrease in
glucose uptake (see section III.2.2), one might expect that in the these hearts a
larger proportion of the sugar taken up (or of the glucose-6-phosphate formed) is
directed towards the synthesis of glycogen than in the control group. We therefore
measured the myocardial glycogen content in both control and LPS groups.
Figure 25 shows the cardiac glycogen content for control and LPS groups, in
vivo and in vitro. In the in vivo conditions (i.e. after rapid excision of the hearts
immediately followed by freezing without perfusion, “before perfusion”), LPS
treatment did not induce any significant change of the baseline glycogen content
(18.8 ± 1.9 vs. 18.3 ± 2.2 µmol/g wet weight). When the excised hearts were first
perfused in vitro for 40 min in the presence of glucose alone (with the last 15
minutes in the presence of insulin), there was a modest increase in glycogen in
both groups. In the control group, the insulin-induced increase in glycogen was
much greater when β-hydroxybutyrate was added to the perfusion, which is in line
with previously reported observations [39]. In contrast, this effect was very small
(and indeed not significant) in the LPS group.
These results thus clearly show that the “re-routing” of glucose towards
glycogen synthesis in the presence of an alternative fuel did not occur in hearts
from LPS-treated rats. This means that not only is glycolysis impaired under these
conditions, but also glycogen metabolism. In addition, it is noteworthy that in
native hearts (i.e. in freshly excised hearts that were immediately frozen without
any perfusion), the glycogen level was not higher in the LPS hearts vs. controls,
despite the fact that in vivo there is a higher blood concentration of free fatty-
acids and a massive hyperinsulinemia (Table 2), two factors that are known to
produce a net glycogen gain in the heart. In other words, this indicates that
myocardial glycogen synthesis is also impaired in vivo upon LPS treatment. 
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6 hours after  saline (control) or LPS injection (LPS) the heart were isolated (Langendorff
modus), and immediately frozen („before perfusion“) or perfused as indicated. After a 40 min
perfusion phase with one (glucose) or two substrates (glucose + β-hydroxybutyric acid), which
included 15 min in the presence of insulin (17 nM), the hearts were frozen and their glycogen
content was measured (see ”Methods“) *: P < 0.05 versus control without β-hydroxybutyric
acid (unpaired t-test). Data are means ± SEM from 4 hearts in each experimental group. 
III.2.5 Signals mediating the LPS effects on cardiac glycolysis 
The next issue addressed was that of the signal(s) mediating the effect of LPS
on cardiac glycolysis.
III.2.5.1  Role of nitric oxide
As mentioned in the introduction, inflammation reactions are able to induce
the expression of a very active the NOS isoform (iNOS), and thus to largely
increase the production of NO (and this also applies to the myocardium). On the
other hand, nitric oxide, or signals induced by it, were reported in many studies to
exert a variety of effects on the the contractility of the cardiac muscle, and may
also modulate glucose metabolism. In order to examine if nitric oxide in our
model could contribute to the glycolytic depression observed in the presence of β-
hydroxybutyrate in the hearts isolated from LPS-treated rats, we used three ways
of investigations:
- the measurement of nitrite production by the isolated hearts in the perfusion
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- the evaluation of the effects of a NOS inhibitor on cardiac metabolism
(glycolysis in particular)
- the quantification of the inducible NOS per Western blotting.
III.2.5.1.1 Inhibitors of NOS  
The data obtained with the NOS inhibitor Nitro-L-arginine methylester (L-
NAME) added to the perfusion at the final concentration 1µM are shown in Figure
26.
This low concentration is known to have no effect on the coronary flow of
isolated control hearts; higher concentrations lead – because of the inhibition of
the basal NO production – to a vasoconstriction and flow reduction. L-NAME had
no effect on the left ventricle pressure or heart rate in any experimental group
(results not shown). In both control and LPS groups, L-NAME did not affect basal
glycolysis either (Figure 26). Under insulin-stimulated conditions the inhibitor
tended to produce an increase of the glycolytic rate, but this effect was not
significant.
Figure 26: Effects of the NOS inhibitor L-NAME, the sphingosine kinase inhibitor NOE,
and the COX-2 inhibitor NS-398 on the glycolysis of isolated rat hearts (in presence of
β-hydroxy butyric acid)
6 hours after  saline (control) or LPS injection (LPS) the hearts were isolated perfused
(Langendorff modus). 4 min before injection of β-hydroxybutyric acid L-NAME (1 µM), NOE
(5 µM), or NS-398 (10 µM) was added to the perfusion. 8 min later the basal and insulin-
stimulated glycolytic rate was measured as described in ”Methods“ *: P < 0.05; **: P < 0.01
(ANOVA). Data are means ± SEM from 4-6 hearts in each experimental group.
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III.2.5.1.2 Cardiac expression of inducible NOS 
As showed on the representative autoradiogram (Figure 27) our Western-blot
analysis failed to reveal any expression of the inducible NOS (nitric oxide
synthase) in the hearts extracts from the LPS group. However, the presence of a
dense band in the range of 130 kD (corresponding to the molecular weight of
iNOS) in extracts from LPS-stimulated Kupffer cells (positive control) confirmed
that this method (consisting in the use of an anti-iNOS antibody) was adequate.
Figure 27: Western-Blot-Analysis of the expression of inducible NOS in heart extracts from
LPS-treated rats and isolated Kupffer-cells (rat liver)
The rats received an intravenous injection of saline (Control) or endotoxin solution (LPS);
6 hours later, the hearts were isolated, perfused for 2 min and immediately frozen in liquid
nitrogen. In each lane a sample of the corresponding total extract (see “Methods”) was
injected. As positive control extracts from isolated Kupffer cells were used (generous gift from
the team of Prof. Gressner, RWTH Aachen, Germany). The Kupffer cells were previously
incubated for 24 h with LPS (1 µg/ml). Showed is a representative autoradiogram. Extracts
from a total of 6 hearts from LPS-treated rats were investigated , always with the same result.
III.2.5.1.3 Cardiac nitrite production 
The measured nitrite concentrations over time in the perfusate in the control
and LPS-treated groups are illustrated in Figure 28. The data recorded over both
perfusion phases (non-recirculating, and recirculating buffer) provide a clear
picture: under these conditions the nitrite concentration calculated for both
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experimental groups remained at a low level (less than 0.2 µM). There was no
detectable net production of nitrite in the control (because the concentration did
not increase), and the LPS treatment failed to induce any massive increase in NO
production. 
Figure 28: Production of nitrite in isolated hearts from sham control and LPS-treated rats
The rat hearts were isolated and first perfused with a non recirculating standard Krebs-Ringer
buffer (negative time points). After 8 minutes a new perfusion started (positive time points) with
a similar buffer (37°C) in a recirculating mode. The nitrite concentration was measured as
described in“Methods”. All values are means ± SEM from 3 hearts in each experimental group.
Heart wet weight was 1.45± 0.03 g in controls, 1.53± 0.02 g in the LPS group.
III.2.5.2 Role of sphingomyelin pathway
The sphingomyelin cascade is one of the signal transduction pathways
involved in some actions of cytokines including tumor necrosis factor. Its role in
mediating TNFα actions has been documented in several insulin-sensitive cell
types, including cardiomyocytes [78, 130, 133]. One of the active metabolites
produced through hydrolysis of sphingomyelin (via activation of
sphingomyelinases) in response to TNFα is ceramide (Figure 29). Recent studies
have revealed the capacity of ceramide (or its further derivatives such as
sphingosine), and of TNFα itself, to antagonise several insulin-dependent events,
such as peripheral activation of glucose transport [64, 68, 145]. Furthermore,
intramuscular ceramide concentrations are elevated in skeletal muscle obtained
from insulin-resistant rats [152]. Incidently, sphingomyelin derivates produced
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after TNFα stimulation are known to mediate acute negative inotropic effects in
both skeletal and heart muscle cells [115, 133].
To determine whether sphingomyelin metabolites could be implicated in the
LPS effect on cardiac glycolysis, we perfused the isolated hearts with the
ceramidase inhibitor N-oleyl-ethanolamine (NOE).
Figure 29: Cytokine-dependent production of sphingomyelin derivatives
As shown in Figure 26, this inhibitor (at the final concentration 5 µM)
measured in the presence of β-hydroxybutyrate had no effect on control hearts, in
basal state, as in insulin-stimulated conditions. In hearts from LPS-treated rats, in
contrast, a perfusion with NOE significantly increased glycolysis, resulting in a
complete restoration of the glycolytic rate to control values. This observation
indicates that sphingomyelin metabolites locally produced in the heart following
systemic inflammation may participate in the LPS-dependent depression of
glycolysis (in the presence of β-hydroxybutyrate). 
III.2.5.3 Role of cyclooxygenase-derived metabolites
III.2.5.3.1  Cyclooxygenase-2
Recently, a causal link was found between TNFα- and ceramidase-dependent
mechanical depression, on the one hand, and cyclooxygenase-mediated production
of eicosanoids, on the other hand, in hearts treated with LPS [56]. Since the
expression of cyclooxygenase-2 (COX-2) is known to be induced by LPS and
inflammatory cytokines in many cell types, including cardiac myocytes [56, 85,
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136] we examined whether COX-2-mediated prostanoid production may be
involved in the effect of LPS on cardiac glycolysis. Figure 26 shows that in hearts
from LPS-treated rats, perfusion with the COX-2-selective inhibitor NS-398 (10
µM) nearly restored the glycolytic flux to control levels (measured in the presence
of β-hydroxybutyrate) whereas in the control group, the inhibitor did not affect
glycolysis (Figure 26). Similar results were obtained with the non-isoform-
selective COX-inhibitor indomethacin (10 µM; not shown).
These results suggest that in our rat endotoxemia model, a COX-2-derived product
may be involved in the increased reduction of glycolytic rate by
β-hydroxybutyrate following LPS-treatment 
III.2.5.3.2 Thromboxane A2
Because thromboxane A2 (TxA2) - a protanoid synthetized downstream of the
COX-dependent reaction - is known to be produced in the heart in response to
inflammatory cytokines such as TNFα [41], we assessed the potential
involvement of this mediator by using SQ-29548 (1 µM), a TxA2 receptor
antagonist [104] in the perfusate (in the presence of β-hydroxybutyrate). In the
basal state (no insulin), the antagonist did not modify the rate of glycolysis in
control hearts, but it eliminated the inhibitory effect of LPS (Figure 30). In the
insulin-stimulated state, SQ-29548 caused a 58% increase in the control group
(Figure 30). To our knowledge, such a potentiation of insulin's effect on
glycolysis (or any other parameters of glucose metabolism) by TxA2 receptor
blockade has not yet been described. On the other hand, in hearts from LPS-
treated rats, SQ-29548 raised the glycolytic flux by 182%, to the same absolute
values as in the control group (Figure 30). Thus, in both basal and insulin-
stimulated conditions, SQ-29548 completely suppressed the difference between
control and LPS hearts.
These results clearly indicate that prostanoids such as TxA2 could be important
mediators of the LPS effect, by potentiating the counterregulatory action of β-
hydroxybutyrate on glycolysis.
Incidently, although it is known that inhibition of prostaglandin synthesis has
beneficial effects in endotoxin shock [5], this is the first demonstration of an effect
of a prostanoid on cardiac glucose metabolism.
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Figure 30: Effects of the TxA2 receptor antagonist SQ-29548 on the glycolysis of isolated rat
hearts (in presence of β-hydroxy butyric acid)
6 hours after  saline (control) or LPS injection the heart were isolated perfused (Langendorff
modus). 4 min before injection of β-hydroxybutyrate SQ-29548 (1 µM) was added to the
perfusion. 8 min later the basal and insulin-stimulated glycolytic rate was measured as
described in ”Methods“ 
*: P < 0.05; **: P < 0.01; ***: P < 0.001 (ANOVA). Data are means ± SEM from 5 hearts in
each experimental group.
III.2.6 Metabolic changes induced in myocytes after LPS treatment
In view of the results obtained in isolated hearts, we decided to further
examine the intrinsic role played by LPS in the metabolic changes observed ex
vivo six hours after the endotoxin challenge in vivo. For this purpose, we tested
the capacity of endotoxin applied in vitro to mimic this exacerbation of the Randle
cycle in a more simple model, namely isolated cardiomyocytes.
The in vitro effects of LPS have been investigated in freshly isolated
cardiomyocytes (from rats) under three conditions: in the presence of only one
substrate namely glucose (condition 1), or glucose and β-hydroxybutyrate
(condition 2 and 3). For all these conditions, the quantity of isolated cells were
similar (Table 6), which allowed a direct comparison of the results obtained in the
different experiments. Furthermore, the absolute values of the glycolytic rate, the
fold-stimulation of glycolysis by insulin (on average between 3 and 5), as well as
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the percentage of inhibition exerted by β-hydroxybutyrate (47 ± 2% for condition
2 and 51 ± 1% for condition 3) were in the range of previous investigations [44].
Table 6: Quantity of isolated cardiomyocytes used for the cell glycolysis measurement
Data are means ±  SEM. Numbers in parentheses indicate number of investigated hearts. For
further details: see text.
Condition 1:
Glu/ LPS1h
Condition 2:
Glucose + β-HB
/ LPS 1h
Condition 3:
Glucose + β-HB
/ LPS 2h
Heart wet weight 
average ( g)
1.24 ± 0.02 (3) 1.25 ± 0.04 (3) 1.32 ± 0.03 (3)
Isolated cells 
(millions/g heart)
2.320 ±0.14 (3) 2.930 ±0.08 (3) 2.380 ± 0.16 (3)
% viable cells
(Trypan blue)
68 ± 4 (3) 73 ± 2 (3) 65 ± 3 (3)
Protein content
(mg/ml)
3.2 ± 0.17 (3) 3.7 ± 0.22 (3) 3.1 ± 0.26 (3)
Using these isolated cardiomyocytes, the direct effect of an in vitro with 1µg/ml
LPS for 60 and 120 min was investigated. As shown in Figure 31, the glycolytic
rate of control and LPS-treated myocytes was identical, even when
β-hydroxybutyrate was added to the medium. In other words even in the presence
of an alternative fuel, the glycolytic depression seen in isolated hearts after an LPS
treatment in vivo did not appear following in vitro application of LPS for up to 2h.
Likewise, indomethacin had no effect on cardiomyocytes (in both control and
LPS-treated cells) whatever the experimental condition.
Taken together, these results suggest that either the duration of the endotoxin
incubation (2 hours) was too short to induced changes in substrate competition in
cardiomyocytes, or LPS alone is not able to produce its metabolic effects and
represents only a trigger for further mediators or factors which are lacking in this
isolated cellular model.
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Figure 31: Effects of insulin, LPS and indomethacin (INDO) on the glycolytic rate of freshly
isolated cardiomyocytes
The cells were incubated at 37 °C in the absence (open bars), in the presence of insulin (33 nM,
bars with points), or in the presence of indomethacin (1 µM) before insulin was added as
described in “Methods”. β-HB (3µM) was added into the cell suspension at t=20 (see section
II.2.2.1.3). Results are means ± SEM from 3 experiments for each condition.
III.3 Contractility of LPS-treated rat hearts
III.3.1 Metabolic effects and contractile function 
As mentioned in the introduction, the investigation of cardiac metabolism
following a LPS-induced systemic inflammation represents the main topic of this
work. The glycolysis is a catabolic process, whose essential role consists in
generating energy in form of adenosine triphosphate (ATP). In the heart, a
substantial part of this energy is converted to mechanical work, and allows the
pumping of the blood through the body. The question hence arose as to whether
the limitation of the glycolytic flux observed in hearts of the LPS group has a
bearing on the mechanical performance of these hearts. Therefore, we recorded
the changes occurring in heart contractility, and examined their relationship with
alterations in energy (and glucose) metabolism. In addition, further (i.e. non-
metabolic) potential mechanisms were also considered . For these purposes, the
traces of the mechanical recordings made during the metabolic experiments (see
“Methods”) are shown and analysed in the next sections.
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III.3.1.1 Action of insulin
Like other insulin-sensitive tissues, for example skeletal muscle, the isolated
hearts respond to the addition of the hormone with a large increase of glucose
uptake and glycolysis, as documented in the studies described above. 
In addition to its metabolic properties, insulin developed a slight positive inotropic
effect in the myocardium (Figure 32). Importantly, under conditions in which the
glycolysis was the most limited, namely when glucose and β-hydroxybutyric acid
were present in the perfusion, and especially in hearts from the LPS group, the
positive inotropism of insulin was the strongest, and significantly so (Figure 32).
This indicates that at least under such conditions, glycolysis may partly limit part
the contractile function of the heart, and that the insulin-dependent increase in
glycolysis causes a partial recovery of this function. On the other hand, in terms of
absolute values of LVDP, even the highest percentual inotropic increase (i.e. in
the LPS group in the presence of β-hydroybutyrate) failed by far to completely
restore the control level of contractility: thus, in the LPS-treated hearts LVDP rose
from 41 ± 3 to 52 ±4 (gain: 11 ± 2 mm Hg), while the basal value of LVDP for the
control (before insulin) was 85 ± 6 mm Hg.
Figure 32: Positive inotropic effect of insulin
6 hours after saline (control) or LPS injection the heart were isolated and perfused
(Langendorff mode) with one (glucose) or two substrates (glucose + β-hydroxybutyric acid).
The left ventricle developed pressure (LVDP) of each experimental group was compared
before, and 4 min after insulin addition. **: P < 0.01 versus corresponding control with β-
hydroxybutyric acid; : §: P < 0.05 vs. LPS group without β-hydroxybutyric acid (ANOVA).
Data are means ± SEM from 8-19 hearts in each experimental group. 
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III.3.1.2 Influence of potential mediators on heart contractility
Since the inhibitors we used in the studies described above (INDO, NS-398,
NOE and SQ-29548) were able to counteract the metabolic effect of LPS on
glycolysis, one may expect that these biochemicals would also restore the
contractility of the heart, if glycolysis depression is a major causal factor of the
mechanical cardiodepression. However, none of the inhibitors caused any sizeable
improvement of the contractility (data not shown). In view of these, and of the
findings made with regard to insulin’s inotropic effect, it appears unlikely that the
reduction of glycolysis is a major contributing factor to the LPS-dependent
mechanical depression. 
III.3.2 Effect of LPS on energetic status
To examine whether the LPS-induced contractile dysfunction of the heart may
be due to a defect in energy metabolism, in particular in ATP formation, we
analysed the content of high-energy phosphates in hearts excised at the end of a
6 hours period following saline or LPS injection. Using a HPLC technique in
collaboration with Dr. Ulrich Decking (University Düsseldorf, Germany), we
found that the total content of ATP, and creatine phosphate was not reduced, and
that of ADP and creatine was not increased in the LPS group (Figure 33).
Incidently, the values measured in both experimental groups for the adenylate and
creatine phosphates are in the range of previously published data [55, 79].
Figure 33: Cardiac content of high energy phosphates
6 hours after saline or LPS injection the hearts were isolated, perfused during 2 min and
rapidly frozen in liquid nitrogen. Data are means ± SEM from 4 control and 3 LPS-treated rats.
Therefore, the myocardial energetic status does not appear to be modified by
the LPS treatment. This contention is further supported by the observation that β-
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hydroxybutyrate is capable of causing a substantial increase in the citrate content
of the hearts (see section III.2.3) which requires an intact mitochondrial function.
Hence, the change in contractile performance following the LPS treatment in vivo
cannot be explained by an impairment of energy provision in the myocardium.
III.3.3 Cardiac response to isoproterenol ex vivo 
As indicated above, under our experimental conditions, the severe cardiac
depression reproducibly observed following LPS-treatment is not largely due to a
metabolic dysfunction. In order to further characterise this cardiodepression, the
influence of the β-adrenergic agonist isoproterenol (used to mimic the action of a
sympathetic activation) on myocardial performance was investigated in the
isolated heart preparation. The short application (5 minutes) of isoproterenol
(0.1 µM) induced an increase of all measured parameters in both experimental
groups (see Table 7). The β-adrenergic agonist nearly restored LVDP to control
values, i.e. it increased this parameter by 90% in hearts from LPS-treated rats, and
by 62% in control hearts (Table 7, Figure 34). Likewise, isoproterenol raised the
velocity of myocardial contraction and relaxation (+dP/dt, -dP/dt), as well as the
coronary flow to the same absolute values as in control hearts (Table 7). Finally,
the isoproterenol-dependent increase in the rate-pressure product (which is a
measure of the myocardial performance) was unaffected by the in vivo pre-
treatment with endotoxin, although isoproterenol did not fully restore this
parameter to control levels (Figure 35).
Table 7: Effects of isoproterenol (0.1 µM) on isolated hearts from  control and LPS-treated
rats
Data are means ±  SEM. Numbers in parentheses indicate number of investigated hearts. For
further details: see text.
Control Control + ISO LPS LPS + ISO
LVDP (mmHg) 69 ± 4 (5) 112 ±8 (5) 48 ± 8(5) 91 ± 10 (5)
Heart rate (beat/min) 234 ± 15 (5) 297 ± 16 (5) 237 ± 18 (5) 287 ± 23 (5)
Coronary flow (ml/min) 12.0 ± 0.4 (5) 13.6 ± 0.5 (5) 10.2 ± 0.3(5) 12.4 ± 0.5 (5)
-dP/dt (mm Hg/sec) 1680 ± 102 (5) 3440 ± 204 (5) 1500 ± 141(5) 3720 ± 320 (5)
+dP/dt (mm Hg/sec) 1933 ± 114 (5) 4467 ± 471 (5) 1533 ± 232(5) 4333 ± 527 (5)
Taken together, these findings suggest that the LPS-induced
cardiodepression does not reflect an irreversible damage to the electromechanical
coupling and contractile machinery. On the other hand, the mechanical
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dysfunction seen ex vivo shows that this cardiac effect of LPS treatment is stable
and not (or no longer) dependent on extracardial factors.
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Figure 35: Effects of isoproterenol on the contractility of isolated hearts from control and
LPS-treated rats
Data are means ±  SEM from 5 hearts in each experimental group.*: P < 0.05 versus control
(unpaired t-test). 
III.3.4 Effect of LPS in vitro on cardiac function
The next question that was addressed was as to whether the functional
impairment of myocardial contractility requires the systemic response to LPS, or
whether it might be a direct effect of the endotoxin on the heart. To assess this, we
perfused rat hearts with a Krebs-Ringer solution containing 1 or 5 mg LPS during
54 minutes and recorded the variations of LVDP, coronary flow and heart rate.
The results obtained are summarised in Table 8. These data show that over a short
period of time (less than 1 hour) LPS is not able to depress the contractility of the
isolated heart (Figure 36).
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Figure 36: Effect of a perfusion with LPS in vitro on isolated hearts
The hearts were isolated and first perfused with a standard Krebs-Ringer solution during
10 min (steady state). Following this perfusion, the hearts were perfused with a similar buffer
(t = 0 on the graph) without addition (control), or with LPS (1 or 5 mg/ml). At t = 54 the
perfusion was switched to the initial buffer (standard Krebs-Ringer without LPS) in order to
detect any possible reversal of LPS effect (LPS clearance). All the buffers were kept at 37°C.
Data are means ± SEM from 2-3 hearts in each experimental group.
When we compared all the recorded values relative to physiological
parameters we could not see any significant differences. Thus, at the end of the
perfusion (t = 49 min) the percentual decrease in LVDP, coronary flow and heart
rate were similar for both groups, normal perfusion and LPS perfusion (see Figure
36 and Table 9). The two concentrations of LPS used for this experiment (1 and 5
mg/l) may indicate that in these conditions there is no dose-response effect (see
Table 8). Finally, the change of perfusion after 54 minutes to a standard Krebs-
Henselheit medium did not show any functional improvement.
Table 8: Effects of LPS perfusion in vitro on the cardiac function
Data are means ± SEM from 2-3 hearts in each experimental group.
Control 
t=0        t=49
LPS 1mg/l 
t=0        t=49
LPS 5mg/l
t=0        t=49
LVDP
 (mm Hg) 
98 ± 7 
(3)
84 ± 6
(3)
89 ± 6
(3)
72 ± 6
(3)
83 ± 5
(2)
67 ± 1
(2)
Coronary flow
(ml/min)
12.7 ± 0.3 
(3)
11.3 ± 0.2
(3)
13 ± 0.5
(3)
11.3 ± 0.7
(3)
13 ± 0.3
(2)
11.5 ± 0.4
(2)
Heart rate
(beats/min)
260 ± 10
(3)
238 ± 12
(3)
267 ± 5
(3)
245 ± 3
(3)
273 ± 3
(2)
250 ± 5
(2)
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Table 9: Percentual decrease of the physiological parameters recorded over 49 min. from
perfused hearts with non recirculating medium
Decrease in %
of:
Control LPS 1mg/l LPS 5mg/l
LVDP 15 ± 3 19 ± 1 19 ± 6
Coronary flow 11 ± 1 13± 5 13 ± 2
Heart rate   8 ± 2  8 ± 2   8 ± 3
III.3.5 Electrophysiological measurements of calcium inward
currents
Calcium influx via transmembrane L-type calcium channels is known to
control the contractile force of the myocardium [18, 42]. On the other hand we
and other investigators demonstrated that administration of endotoxin in animals
leads to a contractile dysfunction of the heart in vivo [53, 58] and in vitro [116,
149]. 
The aim of the following experiments was first to see if the LPS treatment (in
vivo or in vitro) could induce a reduction of the calcium inward currents and
thereby contribute to the cardiodepression observed in isolated rat hearts. For this
purpose calcium currents were measured in cells from three different populations:
- isolated ventricular cells from LPS depressed heart (population 1)
- isolated myocytes from control hearts (population 2)
- and isolated control cells submitted to an LPS treatment in vitro
(population 3).
The second aim, in case of positive results in the first series, was to examine the
possible implication of prostanoids.
III.3.5.1 Effect of LPS on L-type calcium channels
We started these electrophysiological measurements using cardiomyocytes
from LPS-depressed rat hearts, and found a reduction of ICa,L peak densities
compared to control ventricular cells. Since we obtained similar results with
myocytes incubated in LPS (Figure 37), and because of the relative simplicity of
this procedure, we decided to follow our investigations exclusively with heart
cells from populations 2 and 3 (see above).
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Figure 37 shows representative current tracing recorded from a control and a
LPS-treated myocyte ( LPS incubation in vitro, see section II.2.2.2.3).
Figure 37: Representative traces of L-type Ca2+currents measured from control (population
2) and LPS-treated myocytes (population 1 and 3) 3 min after cell membrane rupture 
The statistic results relative to the reduction on L-type calcium channel
currents following the LPS treatment in vivo (isolated myocytes from LPS treated
rats) or in vitro (control myocytes incubated mit LPS; final concentration 1µg/ml)
are summarized in Figure 38. The values obtained for the population 1 and 2 are
in the range of previous studies performed with ventricular myocytes [74, 162].
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Figure 38: Effect of LPS in vivo and in vitro on ICa,L in isolated cardiomyocytes
Mean ICaL densities were measured in freshly isolated cardiomyocytes (control and LPS-
treated, in vivo and in vitro conditions). Hearts cells were obtained as indicated in „Methods“
for all three experimental groups. The LPS-treatment was carried in two different ways: either
the rats received an intravenous injection of LPS (1mg/kg, as in the heart studies in section
II.2.1.1), and cells were isolated 6 hours later (”LPS in vivo“), or myocytes from non-treated
contral rats were incubated during at least 1h with LPS (1µg/ml cell suspension). Numbers in
parentheses indicate total numbers of cells investigated (bold), and the number of independent
heart cell preparations, i.e. of hearts used (light). Data are means ± SEM. *:P<0.05;
**:P<0.01, compared to control.
Reduction of ICa,L could not be explained by dissimilar sizes of control and
LPS cells because membrane capacitance was not different between control
(205 ± 9, and LPS in vivo (188 ± 13 pF), and LPS in vitro (206 ± 11 pF). 
On the other hand, our measurements (Figure 39) showed that LPS applied in
vitro had no influence on current density-voltage relationship, in other words that
the properties of the L-type calcium channels were not modified by the endotoxin.
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Figure 39: Average peak current density-voltage relationships from control (population 2)
and LPS-treated cardiomyocytes (population 3)
III.3.5.2 Effect of cyclooxygenase inhibitors of the LPS-induced
reduction of calcium current density. 
To assess whether the LPS-induced reduction in calcium current is mediated
by a COX-dependent signal, we used the non-selective-isoform COX-inhibitor
indomethacin (which does not discriminate between COX-isoforms). This
inhibitor (0.36 µg/ml), applied 2 min before LPS in population 3 reversed almost
completely the effect of LPS on ICa,L (see Figures 40 and 41).
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Figure 40: Effect of the COX-inhibitor indomethacin (INDO) on the LPS-induced reduction
of L type calcium channels
Mean ICaL densities were measured in freshly isolated cardiomyocytes from populations 2 and
3, treated (INDO) or not with indomethacin (see section II.2.2.2.3). Numbers in parentheses
indicate total numbers of cells investigated (bold), and the number of independent heart cell
preparations, i.e. of hearts used (light). Data are means ± SEM. *:P<0.05; **:P<0.01,
compared to control.
Figure 41 shows the influence of indomethacin on the I-V relationship of ICa,L
This I-V curve was obtained with cell population 2 (n=7) and 3 (n=7) both
stemming from 7 different rat hearts and treated with the COX inhibitor using the
pulse protocol illustrated in the inset. Results indicate that exposure of LPS-
treated myocytes to indomethacin nearly restores (to 86% of non-treated control)
inward calcium current to control level.
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Figure 41: Influence of the COX inhibitor indomethacin (INDO) on average peak current
density-voltage relationships from control and LPS-treated cardiomyocytes
These data show that inhibition of prostanoid synthesis is able to counteract
the negative inotropic action of LPS in isolated rat myocytes and nearly restores
inward calcium current through L-type channels to the level measured in control
ventricular cells. 
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IV Discussion
IV.1 Model validation
A prerequisite for the planned investigations on inflammation-induced
metabolic alterations in the heart was a reliable experimental model showing all
the common features of a systemic inflammation. In the following sections, the
development and the (patho)physiologic characteristics of such a model are
presented.
IV.1.1 General considerations
The principal aim of the present work was to examine the hypothesis that a
generalised inflammatory reaction – which also affects the heart’s mechanical
function – causes metabolic alterations in the myocardium, especially with regard
to the utilisation of the energy substrate glucose. Although experimental protocols
to induce such a systemic, as well as intracardial inflammation have been
described in the literature, the experimental details, such as the type of noxious
agent used, the duration of treatment etc. vary greatly between the studies. We
therefore chose a protocol published by one of the leading groups in the field of
cardiac inflammation (Dr. Meng’s group, University of Colorado, Denver, USA)
[100]. This method essentially consisted of an intraperitoneal application of
bacterial endotoxin (from Salmonella typhimurium) to rats, followed 6 h later by
the excision of the heart, and the assessment of cardiac function and biochemistry
ex vivo. However, preliminary experiments (including variations of the LPS dose,
and the incubation time) showed that although signs of inflammation in the rats, as
well as cardiac depression ex vivo did occur in some cases, these effects were
poorly reproducible. This fact was later confirmed to us personally by Dr. Meng.
We therefore sought to improve the reproducibility of the model by introducing
some modifications.
For instance, we chose the intravenous route of application (via the caudal
vein) instead of the intraperitoneal injection and increased the dosis from 0.5 to
1mg/kg BW. This allowed us to obtain very reproducible effects in vivo and ex
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vivo, as addressed in somewhat more details below. The reason for the
discrepancy observed between the both types of injection is unclear. One
possibility is that the degree of LPS resorption may underlie a greater variation on
intraperitoneal application, especially as the needle may in some cases penetrate
the intestine thus adding a further absorption barrier. Furthermore, the LPS may
be degraded in the peritoneal, or intestinal space before reaching the blood
circulation. It should be noted, though, that the intravenous injection also requires
a very precise placing of the needle and handling of the animal, but given the
necessary skill this route of application guarantees the induction of a generalised
inflammation in nearly 100% of the experiments (see Table 3).
IV.1.2 LPS induced inflammatory reaction and hematologic
alterations in the rat
In experimental research bacterial LPS is the best characterised and most
frequently used substance to mimic pathologic features of inflammatory states,
and in particular to induce fever. All the symptoms observed in LPS-treated rats
when using our modified protocol, including the febrile response (see Figure 18
and Table 2) is in agreement with previous models using sublethal doses of
endotoxin [81, 155].
The results pertaining to the blood picture 6 hours after the LPS injection also
confirm the induction of a pronounced inflammatory response. For instance, the
significant decrease of leucocytes can be explained by the extravasion of these
blood cells from blood vessels. This phenomenon is known to take place during
inflammation states which promote the adhesion of circulating leucocytes and
their active passage (diapedese) through the endothelium into inflamed tissues
[50, 132, 140]. Likewise, the lengthening of the partial thromboplastin time and
the strong decrease in platelets count in the circulation represents the consequence
of a pathologic platelet aggregation encountered during inflammations and known
under the term disseminated intravascular coagulation [47].
IV.1.3 Influence of LPS on endocrinological and metabolic
parameters
Alterations of insulin regulation have been implicated in the pathophysiology
of endotoxin shock, and other critical conditions [21, 159]. Consistent with this
concept we found signs of a severe insulin resistance in LPS-treated rats, as
evidenced by the dramatic increase in insulinemia, in the absence of a decrease in
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the blood glucose level. In fact, the endotoxic rats even showed a mild
hyperglycaemic state, in agreement with previous studies [81]. By the same token,
various agents such as leucine and tryptophan, which stimulate endogenous
insulin secretion and hyperinsulinemia have been shown to exacerbate the
dysregulation of glucose homeostasis and to potentiate the pathogenic effects of
endotoxin [23, 54, 159]. Our measurements, of course, do not allow to determine
the precise interrelationships between these various factors in our model because
we just measured insulin and glucose levels at a single time point, and we thus
have no data on the time course of their changes. Nevertheless, our blood analyses
(see Table 2) are clearly indicative of the development of a generalised insulin
resistance in endotoxic rats. Of note, we also observed a slight increase in the
level of the stress hormone cortisol (see Table 2). Incidentally, the increased
release of couterregulatory hormones like cortisol or glucagon may contribute to
the appearance of the insulin resistance. All these metabolic alterations are of
interest because they were produced by non lethal doses of LPS and are similar to
the metabolic disorders occurring in Gram negative sepsis [4, 82, 139, 143].
Finally, an additional metabolic parameter confirms that our protocol induces
a systemic defence reaction since we identified in the LPS group a significant
elevation of the plasma concentration of non esterified fatty acids (NEFA). This
phenomen results from a mobilisation of the alternative fuels and is characteristic
from  endotoxemia and other stress situations [92].
Taken together, all the LPS-induced changes (hyperinsulinemia, mobilisation
of alternative substrate, realease of stress hormone) and pathological features
(fever, coagulopathy) confirm previous observations of other investigators, and
also the validity of our inflammation model [46, 141].
IV.2 Effect of LPS on glucose utilisation in rat hearts 
As set out in the introduction, inflammatory signals including NO, and
sphingomyelin derivatives, have recently been shown to exert inhibitory effects on
the utilisation of glucose in insulin-sensitive tissues [13, 14, 51, 86, 91]. However,
most of these recent studies have been carried out in vitro, and mainly in skeletal
muscle, or fat tissue preparations or cells. Although the regulation of cardiac
glucose metabolism is in general similar to that of other insulin-sensitive tissues,
and although inhibitory effects may be functionally relevant in the heart, only very
little is known about metabolic changes occurring in the myocardium in the course
of inflammatory processes. Therefore, the main purpose of the present work was
to study whether an inflammation (that also produces such signals as NO, and
78                                                                                                             Discussion
sphingomyelin derivatives in the heart) affects the utilisation of glucose in the
heart. 
The general approach was to induce a systemic inflammatory reaction in a
validated model – as outlined in section IV.1 – and to examine its consequences in
isolated hearts, i.e. ex vivo. They were two main reasons for performing the actual
metabolic studies ex vivo: (i) because a detailed analysis of metabolic effects and
their mechanisms is only feasible under well controlled conditions such as in
isolated perfused organs, and (ii) because functional consequences of an
inflammation such as the mechanical cardiodepression are detectable ex vivo.
IV.2.1 Heart perfusion with glucose as sole substrate
In a first series of experiments, hearts from saline- and LPS-treated rats were
perfused with glucose (5.6 mM) as sole substrate. Under these conditions, we
could not observe any reduction of both metabolic basal and insulin-stimulated
rates of glucose uptake and glycolysis in the LPS group (compared to control). On
the contrary, the insulin-stimulated rate of glucose uptake was even somewhat
increased (Table 7). On the other hand, we noticed in the same experiments a clear
decrease of the mechanical function of the hearts in the LPS group, namely in the
same range as mentioned in section III.1.4. This indicates that at least under these
conditions the mechanical dysfunction of these hearts is not primarily due to a
reduction in the utilisation of exogenous glucose. 
On the other hand, if glycolysis does not appear to be a cause of the
mechanical impairment, one might at least expect that, conversely, a reduction of
the contractile activity (whatever cause it may have) would in turn produce a
downregulation of glycolysis. At least under physiological conditions, there is
namely a tight association between contraction activity (or the resulting energy
demand) and glycolytic rate in the heart [39]. To assess whether this is also the
case in our experimental model, we induced a mechanical cardiac arrest by
perfusing hearts (from saline treated rats only) with a depolarising solution
(15 mM KCl); this intervention led to a drastic reduction of the glycolysis (from
0.31 ± 0.04 to 0.04 ± 0.01 in basal conditions and from 0.73 ± 0.06 to 0.24 ±
 0.02 µmol/g/min in insulin-stimulated conditions) showing that this basic
coupling between mechanical work and glycolysis is, in principle, operative in our
model.
The only known condition under which a reduced mechanical activity does
not lead to a reduction of glucose consumption is that of an energy-depleted state
as it exists in well known pathologic situations (as hypoxia or ischemia) where
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ATP stores (more precisely: the free energy of ATP hydrolysis) are diminished.
However, our measurements of energy-rich phosphates in hearts of the LPS-group
– that were excised and frozen without perfusion 6 h after the LPS-treatment –
have shown that at least the overall energy status does not appear to be
compromised following the inflammation (see Figure 33). In addition,
measurements of the oxygen partial pressure in venous blood from LPS-treated
rats showed values in the normal range compared to control (data not shown) and
thus exclude the hypothesis of an hypoxia due to the LPS treatment. Of course, it
cannot be ruled out that an energy depletion may occur in the course of the
subsequent perfusion ex vivo, although this is unlikely considering the fact that it
would lead to a depletion of glycogen stores, too, which was not observed (see
Figure 25). 
Taken together, these findings indicate (i) that under these experimental
conditions (i.e. heart perfusions with glucose as the sole substrate), the LPS-
dependent cardiodepression cannot be explained by a decreased rate of cardial
glucose utilisation and (ii) that the systemic inflammation causes some sort of
disconnection between glycolysis and contractile activity, in terms of a lack of
glycolytic downregulation in spite of the reduced mechanical work. 
IV.2.2 Heart perfusion with glucose and β-hydroxybutyric acid
Systemic inflammations, as well as other critical disease states, were shown to
be accompanied by endocrinologic and metabolic adaptations which result in the
mobilisation of energy stores (such as fat) [83, 117]. As discussed above (see
section IV.1.3), the hyperinsulinemia and the increase in the level of fatty acids in
the blood indicate that such effects also occur in our model. It has long been
known that cardiac glucose utilisation is depressed under increased supply of
alternative substrates such as fatty acids and ketone bodies (this is a part of the so-
called Randle cycle [39, 120]. In Diabetes mellitus this process may contribute to
the contractile dysfunction of the myocardium [102, 128]. Whether and to what
extent the Randle cycle is operative in the case of systemic inflammations has not
been investigated until now. 
We therefore examined the influence of an alternative substrate
(β-hydroxybutyric acid, for that matter) on glucose utilisation in hearts from
control and LPS-treated rats. In accordance with previous studies, we observed a
clear reduction (by 40-50%) of the absolute basal and insulin-stimulated rates of
glucose uptake when we added β-hydroxybutyric acid as second substrate to the
perfusion (see Results, section III.2.2). However, no difference was seen between
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control and LPS groups under these conditions (see Figure 22). As expected, the
glycolysis of control hearts (under basal, and even more so under insulin-
stimulated conditions) was also reduced by the presence of the ketone body (see
Figure 23). Interestingly, not only was the inhibitory influence of
β-hydroxybutyric acid also seen in hearts of the LPS-group, but it was clearly
(and statistically) stronger than in control hearts, especially under insulin-
stimulated conditions (see Results, section III.2.2). In other words, the LPS
treatment led to an amplification of the cardiac Randle cycle with regard to
glycolysis. 
IV.2.3 Effect of LPS on cardiac glycogen and citrate
In the cardiac Randle cycle, fatty acids or ketone bodies reduce the activity  of
the phosphofructokinase (PFK-1, EC 2.7.1.11; a major regulatory enzyme of
glycolysis) via an increase in the myocardial concentration of citrate
concentration, which allosterically inhibits the enzyme [38]. This inhibitory effect
on the PFK-1 is even re-inforced by the fact that citrate also inhibits the PFK-2
(EC 2.7.1.105), and hence the formation of fructose-2,6-bisphosphate, the most
potent allosteric activator of PFK-1 [38]. 
Our investigations showed clearly that the β-hydroxybutyric acid-induced
increase of citrate was stronger in the LPS-treated hearts as in control (see Results,
section III.2.3). This could be the basis for the greater inhibition of glycolysis. On
the other hand, the mechanism underlying the bigger increase in citrate remains to
be elucidated. Basically, an explanation for this could be an increased
mitochondrial oxidation of the ketone body, or also a decrease of the citrate
turnover in the tricarboxylic acids cycle.
Considering the greater inhibition of glycolysis without a simultaneous
change in the rate of glucose uptake (i.e. transmembrane transport + intracellular
phosphorylation to glucose-6-phosphate) we decided to check if in the LPS-
treated hearts a larger part of the glucose-6-phosphate formed was directed
towards glycogen synthesis. The measurement of the glycogen contents in the
isolated hearts showed that it was not the case: thus the re-routing of glucose-6-
phosphate into glycogen synthesis in the presence of an alternative substrate
occurred in control hearts – in agreement with previous observations [39], but was
not or barely detectable in the LPS-treated hearts (see Results, section III.2.3).
That means that under these experimental conditions glycogen metabolism is also
impaired through the pre-treatment with LPS.
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Since the net synthesis of glycogen in such heart perfusions (as it was
observed in the control group) – as well as in vivo – is largely dependent on
insulin, the noticeable effect of LPS can be interpreted as a sign of a cardiac
insulin resistance. In this context, another observation is also of interest: the native
cardiac glycogen content (i.e., as measured immediately after the heart excision,
and before the ex vivo perfusion) was not greater in the LPS group than in the
controls (see Figure 25), despite the much higher in vivo insulin and alternative
substrates levels (non-esterified fatty acids) seen after the endotoxin treatment
(Table 2). This indicates that the cardiac insulin resistance of glycogen synthesis
observed ex vivo is also effective under in vivo conditions. Whether this
resistance is due to the inhibition of the glycogen synthesis, or to an increased
breakdown cannot be deduced from our data, and should be addressed in future
studies. Since, beside glycolysis and glycogen synthesis, the third metabolic route
of glucose utilisation, namely the pentose-phosphate pathway, is of minor
significance in the heart in terms of total balance and hence does not represent an
appreciable sink for glucose-6-phosphate, the question of the eventual fate of
glucose-6-phospahte remains unsolved. A hypothetical possibility would be that a
possibly increased rate of glycogen synthesis may be hidden by a simultaneous
glycogen breakdown, which would amount to a futile cycle. Only a direct
measurement of the rate of glycogen synthesis, as well as of the levels of hexose-
phosphates, could provide an answer to this question.
IV.2.4 Signals mediating the LPS effects
IV.2.4.1 Nitric oxide
The involvement of nitric oxide – produced in large quantities by the
inducible NO synthase – in the pathogenesis of sepsis and inflammation in target
organs including the myocardium, has been suggested by some studies (see e.g.
[76, 137]), although contradictory reports exist concerning the role of NO
synthase in inflammation models [98]. Because the second messenger of NO,
namely cGMP, was recently shown to inhibit cardiac glucose transport and
glycolysis [16, 36], we examined the possible role of NO and iNOS in the
exacerbation of the Randle cycle seen after the LPS treatment in rats.
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Our results seem to exclude NO as mediator of this metabolic effect. Thus,
our investigations demonstrated: (i) no increase of the nitrite concentration in the
perfusion, (ii)no induction of the iNOS activity in myocardium, (iii) no effect of
the NOS inhibitor L-NAME on cardiac glucose metabolism. Incidentally, the lack
of effect of LPS on glucose uptake and glycolysis in the absence of
β-hydroxybutyrate is consistent with a lack of iNOS expression, because if the
NO system was activated, one should expect the NO-induced second messenger
cGMP to depress glucose uptake and glycolysis, because this effect was observed
with glucose as the sole substrate (or even in the absence of glucose) in
cardiomyocytes and isolated hearts [16, 36].
The pronounced mechanical cardiodepression seen in our model in the
absence of a iNOS induction confirms previous observations that other factors
beside the NO system must be responsible for the impairment of the contractile
function [35, 56, 98]. 
IV.2.4.2 Role of the sphingomyelin pathway
As mentioned in III.2.5.2 inflammatory cytokines (such as TNFα)  are known
to stimulate the intracellular production of sphingomyelin derivatives in many cell
types including heart muscle cells. 
Recently, we (Thurner et al., manuscript in preparation) and others [158]
demonstrated that sphingomyelin-derived products were able to impact on glucose
transport in insulin-sensitive cells including isolated rat cardiomyocytes.
The new finfing of our investigations concerning the sphingomyelin pathway
lies in the fact that a blockade of the enzyme ceramidase with the specific
inhibitor NOE is sufficient to completely restore the glycolytic rate (to the control
level), which was previously shown to be reduced by the LPS. 
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IV.2.4.3 Role of the cyclooxygenase-derived metabolites
Recent studies have shown that the cytokines-stimulated production of
sphingomyelin derivatives is accompanied by an increased formation of
prostanoids [7, 105, 108]. Furthermore, arachidonic acid, which is known to be
liberated from membrane lipids in response to various pathological stimuli and
especially inflammatory mediators, and to be metabolised by cyclooxygenases,
was also found to downregulate insulin-dependent glucose transport [145]. More
recently, significant expression of COX-2 has also been demonstrated in septic
human and endotoxic rat heart [87].
Our measurements of the cardiac metabolism are not only in line with these
observations but also demonstrated, that a sphingomyelin derivative as well as a
COX-dependent signal mediate the exacerbation of the counterregulatory effect of
alternative fuels on glycolysis. The fact that we could totally reverse the inhibiting
effect of the LPS inflammation by using inhibitors of the one or the other
signalling pathway may indicate that these signals are successively triggered with
regard to glycolysis regulation. An acute coupling between sphingomyelin
derivatives and a COX-mediated production of eicosanoids has at least been
described for other tissues and cell types [26, 34]. A further implication of the
finding that the effect of LPS in vivo could be totally reversed by the ex vivo
application of inhibitors of the sphingomyelin and eicosanoid pathways is that
factors such as the TNFα, COX-2, and signalling metabolites are induced or
produced locally in the myocardium and have become independent of the primary
stimulus in vivo (e.g. LPS or possibly non-cardiac factors induced by it).
Taken together, these results suggest that both the sphingomyelin pathway and
COX-mediated TxA2 production play a role in the LPS-dependent potentiation of
β-hydroxybutyrate's depressing action on cardiac glycolysis. The overall
interpretation of all our results concerning the effects of LPS on cardiac glucose
metabolism allowed us to elaborate a concept summarising a possible cascade of
intracellular events triggered by the LPS from the cytokines release to the
glycolysis depression observed in presence of β-HB (see Figure 42).
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Figure 42: Hypothetical relationship between LPS and myocardial glucose metabolism.
LPS is known to induce the expression of inflammatory cytokines such as TNF-α. After release
and binding to their specific receptors located in the membrane of the cardiomyocyte, the
cytokines are able to stimulate the hydrolysis of sphingomyelin (SM) into ceramide by the
enzyme sphingomyelinase (SMase).
The fact that blockade of either the ceramidase pathway (with NOE) or the COX-2-mediated
prostanoid formation or TXA2 receptors completely prevents LPS-induced glycolytic inhibition
indicates that both pathways may be in series, i.e. located in a single chain of events; at least
individual segments of such a pathway have been described in inflammatory processes, such as
the cytokine-induced, PLA2-mediated formation of arachidonic acid [151, 163], which may be
fed into a COX-2-dependent pathway leading to TXA2 formation [63, 131].
As shown by our experiments, LPS enhances the citrate formation from β-HB and hence
potentiates (possibly via thromboxane A2) the negative influence of the carboxylic acid on
glycolysis. 
The signal (s) linking LPS with the impairment of myocardial glycogen metabolism remain to
be investigated.
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IV.2.5 Metabolic changes induced in myocytes after LPS treatment
In order to assess whether the LPS applied in vivo may exert a direct effect
on the heart (i.e. an action that would not depend on the systemic inflammation
reaction), isolated cardiomyocytes (from non-treated animals) were incubated
with LPS in vitro. The experiments showed that this type of treatment had no
influence on myocytes´ glucose metabolism, nor on the substrate competition (see
Results, section III.2.6). This lack of metabolic changes at the cellular level
(cardiomyocytes) may be explained in several ways. First, the duration of the LPS
incubation (up to 2 h) may have been too short to induce a metabolic response;
alternatively, these findings may indicate that LPS alone is not able to produce the
glycolytic depression observed upon in vivo treatment with the endotoxin and
may require a mediator or additional factors, as for example cytokines, or non-
myocyte cells (e.g. macrophages). Thus these in vitro experiments with isolated
cells did not allow to further delineate the chain of events leading to the metabolic
action of in vivo treatment with LPS. Therefore, further investigations in vivo and
ex vivo will be required to elucidate these mechanisms.
IV.2.6 Relationship between glycolysis and cardiac contractility
after LPS treatment
The large depression of the left ventricular contractility observed ex vivo
following the in vivo treatment with endotoxin is unlikely to be due to an
impairment of glycolysis because this contractile dysfunction was also observed
under conditions where glycolysis was not altered in the LPS group, namely if
glucose was used as the sole substrate (see Table 7). 
However, under certain conditions, glycolysis may start contributing to a
limitation of the mechanical function. Thus, addition of β-hydroxybutyrate –
which reduced the rate of glycolysis – also produced per se a further decline in
LVDP (not shown). Conversely, insulin had its most pronounced positive
inotropic effect in the experimental group in which the basal glycolytic rate was
the lowest, i.e. in LPS hearts perfused with β-hydroxybutyrate (see Figure 32). It
is of interest that previous studies performed in canine heart preparations
following endotoxin treatment have shown a partial recovery of mechanical
parameters with insulin infusions [2]. In other words, it is conceivable that when
the rate of glycolysis is particularly low – e.g. due to the exacerbation of the
Randle cycle following the LPS treatment in our model – the reduced glycolytic
flux may contribute to the cardiodepression. However, it should be stressed that
even under these conditions, the relatively large increase in glycolysis brought
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about by insulin (+ 78 % compared to basal) was only accompanied by a very
partial restoration of the mechanical performance (up to a level of 52 ± 4 mm Hg,
whereas the control LVDP values measured in the presence of β-hydroxybutyrate
was 85 ± 6 mm Hg). Thus, even here glycolytic inhibition is almost certainly not
the major cause of the mechanical failure. 
Nevertheless, an impaired glycolysis may become very critical under ischemic
conditions. Earlier studies have indicated that the functional recovery following an
episode of ischemia is also dependent on the rate of glycolytic activation [88, 66].
One may therefore speculate that the heart of LPS-treated animals – and perhaps
of septic or injured patients – should be more sensitive to ischemic events. In this
context, it is noteworthy that in critically ill patients, intensive insulin therapy was
recently shown to improve the clinical outcome (i.e. decreased morbidity and
mortality) [154]. Since heart failure is one of the death causes in such patients
[150], it is possible that the cardiac action insulin is one of the underlying
beneficial effects of the hormone in this setting.
IV.2.7 Mechanisms underlying the LPS-induced cardiodepression
IV.2.7.1 Studies in isolated hearts 
The fact that contractility and coronary flow of hearts isolated from LPS-
treated hearts could be increased by the β-adrenergic agonist isoproterenol nearly
up to control levels (at least for a short time of 5 min.) (see Results,
section III.3.3) means that the cardiodepression is not due to an irreversible defect
of the electromechanical coupling, or the contractile apparatus and that the
coronary reserve is, at least in part, preserved. 
As discussed above, the analyses of the cardiac high energy phosphates
showed that the hearts were not depleted six hours after the LPS injection (see
Results, section III.3.2). These results concerning the energetic status of
endotoxin-treated rat hearts confirm the previous observations of other
investigators [127, 147]. Thus a general impairment of the cardiac energy
metabolism cannot be made responsible for the cardiodepression either.
However, the literature also contains contradictory examples in which LPS
reduced the inotropic responsiveness to a β-adrenergic stimulation [15] with or
without modification of the energetic status of isolated hearts [122, 127].
Nevertheless, it is clear that in our model, the possibilities addressed above
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(impaired contractile apparatus, electromechanical coupling, energy status) do not
apply as causal factors to explain the mechanical dysfunction.
IV.2.7.2 Studies in isolated cardiomyocytes: effects of LPS on L-type
calcium channels
The above results prompted us to consider yet another possible factor that is
pivotal for heart contractility, namely the influx of calcium ions into heart muscles
cells via calcium channels. 
Calcium channels are cell membrane glycoproteins selectively permeable to
calcium ions. They regulate the intracellular calcium concentration and contribute
thereby to the calcium signalling of these numerous cell types. These channels are
widely distributed in the animal kingdom and are an essential part of many
excitable and non-excitable mammalian cells. The opening of a subset of these
channels, the so-called voltage-sensitive (or voltage-gated) calcium channels is
primarily regulated by the membrane potential, but is also modulated by a wide
variety of hormones [27], protein kinases [62], protein phosphatases [3], toxins
and drugs [12, 61]. The native currents of the voltage-sensitive calcium channels
have been subdivided into distinct classes by biophysical and pharmacological
criteria: L (long lasting)-type, P (Purkinje)-type; T (transient)-type, N (neither)-
type, Q- and R (remaining)-type. N-, P-, Q-, and R-type are located in neuronal
and endocrine tissues [90, 110, 123]. T-type calcium channels are present
throughout the cardiovascular and central nervous system [112, 153]. L-type
calcium channels are found in heart, skeletal and smooth muscles, in fibroblasts
and kidney, but also in neuronal and endocrine tissues [11, 12, 109]. In the heart,
the L-type calcium channels are necessary for the generation of electrical impulses
and for the initiation of contraction in atrial and ventricular muscle [126, 138].
To the best of our knowledge T-type calcium current (ICa,T) has not been
found in rat cardiomyocytes membrane. On the other hand it is known that its
kinetic behaviour is very different from that of L-type channels [103]. Finally the
pulse protocol we applied in the present study allowed us to exclude other currents
than the L-type.
As described in section III.3.5.1, we found that LPS is able to induce a
significant reduction of inward calcium currents through L-type calcium channels
in rat cardiomyocytes. This effect that we observed ex vivo (on ventricular cells
isolated from endotoxemic rat hearts) as well in vitro (LPS treatment of isolated
cardiomyocytes), allows us to think that this cardiodepressive action is
independent from systemic processes, other cell types, or inflammatory mediators
circulating in the blood. Note that a similar reduction of ICa,L  induced by LPS was
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already observed ex vivo in another mammalian species [162] and that some
examples of circulating TNFα-independent effect of LPS on the myocytes
contractility exist in the literature [111]. Although cardiodepressant effect of
endotoxin have been documented in many settings in vivo [155], ex vivo [129]
and in vitro [25, 106] only few studies support the idea that LPS can directly
inhibit cardiomyocyte contraction [144, 149, 157]. On the other hand, these
effects of LPS do not exclude that LPS-induced cytokines produced endogenously
may also affect the contractile function of the cardiomyocytes [52, 148]. The fact
that the effect of LPS in vitro already appears after a short period following LPS-
incubation (1-2 hours) is in concordance with previous experiments which
demonstrated early manifestation of cardiac hypocontractility [142, 147].
The cellular signalling events leading to LPS-induced myocardial contractile
dysfunctionis still incompletely understood. In principle, several possible LPS-
induced pathways have been described such as that mediated by. specific
receptors as the antigen glycoprotein CD14 and Toll-like receptors [28, 118] or
alternatively via other CD-14 independent processes leading to internalisation and
transfer of LPS to specific intracellular sites [30, 31]. Our results do not allow to
determine which of these pathways may be involved in the regulation of cardiac
calcium channels.
A novel finding of our study consists in the partial restoration of the calcium
influx induced by the COX-inhibitor indomethacin, which directly implicates
prostanoids in the reduction of calcium channels activity. Although it has been
well established that arachidonic metabolites participate in the pathophysiology of
shock induced by lipopolysaccharides [49, 56, 87] a direct in vitro demonstration
of such a link between LPS and protanoids at the level of cardiac myocytes has
never been made. Of interest, prostaglandins are known to mediate many cardiac
pathologies [29, 72, 134], exert various inotropic actions on the heart [73, 113,
134], and also modulate cardiac L-type Ca2+ channels of several mammalian
species [1, 156, 160]. Thus, it is conceivable that LPS-induced prostaglandins
alter ICa,L activity in rat cardiomyocytes. In this context, it remains to be
determined whether this effect is direct (i.e. that LPS can acutely induce the
production of prostanoids) or mediated, for instance by an induction of the
cyclooxygenase-2. In principle, 1 or 2 hours of incubation in the presence of LPS
is long enough to induce de novo synthesis of new proteins [72, 107], and indeed
our preliminary results using the protein synthesis inhibitor cycloheximide (data
not shown) seem to confirm this hypothesis. 
Whether or not some intermediary proteins or a potential paracrine effect [32]
could play a role in our model remains to be established. 
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IV.3 Conclusion and outlook
This work showed that a systemic inflammation, as induced by in vivo
administration of LPS, can influence the cardiac glucose metabolism, especially
the effect of insulin, through at least two mechanisms:
- the reinforcement of the counterregulatory effect of alternative fuels, such as
ketone bodies, on glycolysis (i.e. exacerbation of the Randle cycle); 
- the impairment of insulin-dependent glycogen synthesis.
These inflammation effects could be demonstrated ex vivo (in isolated hearts).
Glycolytic inhibition can be:
1. explained by an increased production of the PFK inhibitor citrate
2. and mediated by the sphingomyelin pathway, as well as the COX-2-
dependent production of TXA2.
The precise sequence of events (or signals) leading to these effects will have to be
addressed in subsequent investigations, as well as the mechanism underlying the
alteration of glycogen synthesis. The pathophysiological significance of these
metabolic changes in vivo also remains to be determined. Glycolytic impairment
does not appear to be responsible for the mechanical dysfunction seen under
certain conditions ex vivo, but may become important in the context of a limited
oxygen supply as for instance in myocardial ischemia in vivo. 
As for the mechanical dysfunction caused by the in vivo LPS treatment, and
detectable ex vivo in isolated-perfused hearts, the present investigations indicate
that it may be at least in part due to a direct cardial action of the endotoxin on the
L-type calcium channel of the heart muscle cells, i.e. a diminution of the calcium
influx, and therefore of the contraction triggered by this calcium. This process
may involve COX-derived prostanoids. The signalling chain and the molecular
mechanism of this decreased calcium current needs to be further defined. For
instance, future studies should clarify whether de novo protein synthesis is
required (e.g. expression of COX-2), and the prostanoid(s) involved; furthermore,
the relevance of this mechanism for the in vivo cardiodepression should also be
established. A thorough clarification of these issues is the prerequisite for the
evaluation of possible therapeutic applications based on the understanding of
these metabolic and contractile mechanisms. 
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V Summary
Acute and chronic inflammations of the myocardium are often associated with
a severe impairment of cardiac contractility. Such inflammatory processes may be
either local, i.e. limited to the heart, or part of a systemic response to an infection
or injury. In all cases, key players in these events are proinflammatory cytokines
such as tumor necrosis factor (TNFα) and interleukin-1β (IL-1β), which are in
part produced by the cardiomyocytes themselves. Beside heart failure, sepsis and
trauma induce complex and profound metabolic changes, including a mobilisation
of the body’s energy reserves. Despite the fact (i) that the utilisation of fuels by
the heart is one of the determinants of its contractile capacity, particularly in
pathophysiological conditions, and (ii) that inflammatory cytokines are known to
affect glucose metabolism in other insulin-sensitive tissues (e.g. muscles),
relatively little is known about metabolic alterations occurring in this organ in the
course of a local or systemic inflammatory response.
The aim of the present work was therefore to examine the influence of a
systemic inflammation, induced by administering a bacterial endotoxin
(lipopolysaccharide; LPS) to rats, on the cardiac utilisation of glucose and its
significance for the mechanical function of the myocardium.
First, an experimental protocol was established and improved, in which
intravenous injection of LPS (from S. typhimurium, 1 mg/kg body weight) caused
a reproducible generalised inflammatory reaction (fever, thrombopenia etc.), as
well as a dramatic hyperinsulinemia, which in the absence of large changes in
glycemia, is a clear sign of severe insulin resistance. A mobilisation of fat reserves
also occurred, as evidenced by a large increase in the plasma level of non-
esterified fatty acids. In addition, LPS treatment led to a clear cardiodepression
(reduction of the left ventricular developed pressure by ~50%) which could be
demonstrated ex vivo, i.e. in hearts isolated 6 h after the LPS-treatment and
perfused in the Langendorff mode. 
In control hearts (from saline-treated rats) perfused with the ketone body
β-hydroxybutyrate (β-HB, 5 mM, in addition to 5.6 mM D-glucose) to mimic the
in vivo conditions of fat mobilisation, the rate of non-stimulated, and of insulin-
stimulated glycolysis from 3[3H]-D-glucose was decreased by about half as
compared to perfusions using glucose as the sole substrate. This is consistent with
the known counterregulatory effect of substrates such as β-HB and fatty acids on
92                                                                                                               Summary
cardiac and muscular glycolysis (Randle cycle). Interestingly, glycolytic
depression by β-HB was significantly more pronounced in hearts from LPS-
treated rats, the rates of glycolysis being ~ 45% lower than in control hearts under
the same conditions. In the absence of β-HB (i.e. with glucose alone), the
glycolytic rates did not significantly differ between the control and LPS group.
Nor did LPS treatment lead to a diminution of glucose uptake (i.e. transmembrane
transport + phosphorylation to glucose-6-phosphate) by perfused hearts, as
estimated using 2-[3H]-D-glucose. 
In hearts from LPS-rats, β-hydroxybutyrate produced a larger increase of the
citrate content (by 40%) compared to controls, which may be the mechanism
underlying the stronger glycolytic inhibition in the LPS group, because alternative
substrates are known to depress the phosphofructokinase reaction (a major
regulatory step of glycolysis) via an increase in this allosteric inhibitor. 
In control hearts, β-hydroxybutyrate addition reinforced the insulin-dependent
increase in glycogen (which may be explained by the reduction of the glycolytic
pathway and re-routing of glucose towards glycogen synthesis); this effect was
not observed in the LPS group, indicating that the endotoxin also causes an insulin
resistance at the level of glycogen metabolism.
In order to identify the signals involved in the action of LPS on cardiac
glycolysis, the major pathways directly and indirectly triggered by TNFα and IL-
1β were examined. Measurements of nitrite levels in the coronary effluent of
isolated hearts showed that LPS treatment in vivo failed to increase the cardiac
production of nitric oxide (NO); moreover, LPS did not induce the expression of
the cytokine-sensitive NO synthase (iNOS). The NO synthase inhibitor L-
nitroarginine-methylester (1 µM) did not affect the LPS-dependent glycolytic
inhibition by β-HB. In contrast, perfusion with the ceramidase inhibitor N-oleyl-
ethanolamine (5 µM) – which was used because ceramide and further downstream
metabolites are known to be produced in response to TNFα-activated
sphingomyelin degradation – restored the glycolytic rate to control levels. Since
TNFα-mediated responses were reported to be associated with the induction of the
cyclooxygenase-2, the involvement of this pathway was examined too. Perfusion
(ex vivo) with the COX-2 inhibitor NS-398 (10 µM), and the thromboxane A2
receptor antagonist SQ-29548 (1 µM) also suppressed the LPS-dependent
glycolytic reduction. These data indicate that the effect of LPS on glycolysis may
be mediated by a sphingomyelin derivative, and COX-2-derived thromboxane A2. 
Finally, the mechanism underlying the mechanical depression following the
endotoxin treatment was addressed. This dysfunction was also detected under
conditions where glycolysis did not differ between control and LPS groups (i.e.
Summary                                                                                                                93
perfusion with glucose as sole substrate), indicating that a change in glycolysis is
not the major cause of mechanical failure. However, insulin addition – which
stimulates glycolysis ~2-fold – increased the ventricular developed pressure, and
this effect was most pronounced in the LPS group in the presence of β-HB, i.e.
when the basal glycolytic flux was lowest; this indicates that under certain
conditions, glycolytic reduction may start contributing to a contractile limitation.
Further experiments showed that in isolated hearts β-adrenergic stimulation
with isoproterenol caused a large increase in ventricular developed pressure (and
nearly abolished the difference between control and LPS groups), and also
restored the coronary flow, showing that the cardiodepression cannot be explained
by an irreversible damage to the electromechanical coupling, the contractile
apparatus, or the coronary reserve. Additional studies were therefore performed in
isolated cardiomyocytes in which calcium influx through voltage-sensitive
calcium channels (L-type channels) – which is one important determinant of
contraction initiation and amplitude – was measured. It was found that an
incubation of these cells in vitro with LPS (1 µg/ml) for 1-2 h reduced this
calcium current by 50%. This effect was prevented by co-incubation with the
(non-isoform-selective) cyclooxygenase inhibitor indomethacin (0.36 µg/ml).
These observations suggest that LPS itself may produce a prostaglandin-mediated
cardiodepression through inhibition of calcium channels. Since under the same
conditions (i.e. in vitro) LPS failed to produce a metabolic effect on glycolysis, it
appears that the pathways leading to the mechanical impairment, on the one hand,
and the glycolytic depression, on the other hand, are not identical. 
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